Page 1 Extracted Terms:
- Heart Failure  
- Heart disease  
- Cardiovascular disease  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA)  
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure  
- 2013 ACCF/AHA Guideline for the Management of Heart Failure  
- 2017 ACC/AHA/HFSA Focused Update of the 2013 Guideline  
- Clinical Practice Guidelines  
- Evidence‑based recommendations  
- Patient‑centric recommendations  
- Prevention of heart failure  
- Diagnosis of heart failure  
- Management of heart failure  
- Morbidity and mortality related to heart failure  
- Quality of care in heart failure  
- Economic analysis of heart failure treatments  
- Clinical trials and research studies in heart failure  




Page 2 Extracted Terms:
- heart failure  
- heart failure with reduced ejection fraction (HFrEF)  
- heart failure with preserved ejection fraction (HFpEF)  
- heart failure with mildly reduced ejection fraction (HFmrEF)  
- systolic heart failure  
- chronic heart failure  
- acute decompensated heart failure  
- cardiogenic shock  
- cardiac failure  
- heart failure rehabilitation  
- beta blockers  
- mineralocorticoid receptor antagonists (MRAs)  
- ACE inhibitors (ACEi)  
- angiotensin receptor blockers (ARBs)  
- angiotensin‑neprilysin receptor antagonist (ARNi)  
- sacubitril/valsartan  
- sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- cardiac amyloidosis  
- atrial fibrillation  
- congestive heart failure  
- guideline‑directed medical therapy (GDMT)  
- cardiomyopathy  
- valvular heart disease  
- mitral regurgitation  
- cardiac imaging (echocardiography, MRI, CT, etc.)  
- invasive cardiac evaluation (catheterization)  
- biomarkers for heart failure (BNP, NT‑proBNP)  
- diuretics and decongestion strategies  
- hydralazine and isosorbide dinitrate  
- ivabradine  
- digoxin  
- soluble guanylyl‑cyclase stimulators  
- implantable cardioverter‑defibrillators (ICDs)  
- cardiac resynchronization therapy (CRTs)  
- revascularization for coronary artery disease (CAD)  
- right‑heart pressure assessment  
- exercise and functional capacity testing (6‑minute walk, CPET)  
- cardiac rehabilitation  
- dietary sodium restriction  
- self‑care support in heart failure  
- Stage A (at‑risk) heart failure  
- Stage B (pre‑clinical HF)  
- Stage C (symptomatic HF)  
- heart failure with mildly reduced ejection fraction (HFmrEF)  
- heart failure with improved ejection fraction (HFimpHF)  
- HF risk scoring  
- wearable and remote monitoring technologies  
- wearables, telemonitoring, device monitoring  
- cardiogenic shock management  
- cardiac amyloidosis management  
- cardio‑oncology considerations  
- social determinants of health (contextual factor)  
- palliative care for advanced heart failure  



Page 3 Extracted Terms:
**Key heart‑disease terms identified in the guideline excerpt**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Preserved EF (HFpEF)  
- Ejection fraction (EF)  
- Systolic/diastolic function  
- Cardiac amyloidosis (amyloid heart disease)  
- Screening for serum and urine monoclonal light chains  
- Bone scintigraphy (for amyloidosis)  
- Genetic sequencing (for amyloidosis)  
- Tetramer stabilizer therapy (for amyloidosis)  
- Anticoagulation (for amyloidosis)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- ARA–neprilysin inhibitor (ARNi)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin receptor blocker (ARB)  
- Mineralocorticoid receptor antagonist (MRA)  
- β‑blockers  
- Nitrates (routine use contraindicated, class III)  
- Phosphodiesterase‑5 inhibitors (class III)  
- Natriuretic peptides (BNP, NT‑proBNP)  
- Hemodynamic measurement (invasive filling pressures)  
- Non‑invasive filling pressure assessment (diastolic imaging)  
- Advanced HF (Stage D)  
- Mechanical circulatory support (e.g., LVAD)  
- Inotropic support (e.g., dobutamine, milrinone)  
- Cardiac transplantation  
- Cardiogenic shock  
- Venous thromboembolism (VTE) prophylaxis  
- Atrial fibrillation (AF) management  
- Cardio‑oncology (cancer therapy‑related cardiac disease)  
- Heart failure during pregnancy  
- Palliative and supportive care (advanced HF)  
- Primary prevention for HF stages A/B  
- Quality metrics and patient‑reported outcomes  
- Evidence gaps and future research directions  

These terms encompass the diagnostic, therapeutic, and management concepts related to heart disease outlined in the provided guideline text.

Page 4 Extracted Terms:
- Heart Failure (HF)  
- “At risk” for HF (Stage A)  
- Pre‑HF (Stage B)  
- Iron deficiency  
- Anemia  
- Hypertension  
- Sleep disorders  
- Type 2 diabetes  
- Atrial fibrillation  
- Coronary artery disease  
- Malignancy  
- Cardiovascular disease (CVD)  
- AHA/ACC/HFSA Heart Failure Guideline  
- Clinical practice guidelines  
- Cardiovascular health  
- Shared decision‑making  
- Patient engagement  
- Evidence‑based methodologies  
- Value assessment of drug/device/intervention  

Page 5 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mildly reduced ejection fraction  
- Systolic heart failure  
- Diastolic (preserved‑ejection) heart failure  
- Chronic heart failure  
- Acute decompensated heart failure  
- Cardiogenic shock  
- Cardiac amyloidosis  
- Valvular heart disease  
- Mitral regurgitation  
- Cardiomyopathy (general)  
- Cardiomyopathy in pregnancy  
- Right‑heart pressure / right‑ventricular dysfunction  
- Atrial fibrillation  
- Congestive heart failure  
- Reduced ejection fraction  
- Guideline‑directed medical therapy (GDMT)  
- Beta‑blockers  
- Mineralocorticoid‑receptor antagonists  
- ACE‑inhibitors  
- Angiotensin‑and‑neprilysin receptor antagonist (sacubitril/valsartan)  
- Angiotensin‑receptor antagonist  
- Sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors  
- Diabetes mellitus (as a comorbid condition in heart disease)  
- Palliative care (in the context of advanced heart failure)

These terms capture the principal cardiac conditions, therapeutic categories, and relevant comorbidities highlighted in the guideline excerpt.

Page 6 Extracted Terms:
- Heart Failure (HF)  
- Stage C heart failure  
- Stage D heart failure  
- Prevention of heart failure  
- New heart failure treatment strategies (SGLT2 inhibitors, ARNI)  
- Atrial fibrillation (AF)  
- Mitral regurgitation (MR)  
- Mitral valve (MV) clipping  
- MV transcatheter edge‑to‑edge repair  
- Cardiac amyloidosis  
- Cardio‑oncology  
- Implantable devices  
- Left ventricular assist device (LVAD)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Acute coronary syndrome (ACS)  
- Angiotensin‑receptor neprilysin inhibitor (ARNI)  
- Angiotensin (II) receptor blocker (ARB)  
- Amyloid cardiomyopathy (AL‑CM)  
- Transthyretin amyloid cardiomyopathy (ATTR‑CM)  
- Variant transthyretin amyloidosis (ATTRv)  
- Wild‑type transthyretin amyloidosis (ATTRwt)  
- B‑type natriuretic peptide (BNP)  
- Coronary artery bypass graft (CABG)  
- Coronary artery disease (CAD)  
- Cardiac contractility modulation (CCM)  
- Congestive heart failure (CHF)  
- Cardiovascular magnetic resonance (CMR)  
- Cardiopulmonary exercise test (CPET)  
- Cardiac resynchronization therapy (CRT)  
- CRT‑D (CRT with defibrillation)  
- CRT‑P (CRT with pacemaker)  
- Central venous pressure (CVP)  
- Direct‑acting oral anticoagulants (DOAC)  
- Electrocardiogram (ECG)  
- Ejection fraction (EF)  
- Heart failure with improved ejection fraction (HFimpEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Left bundle branch block (LBBB)  
- Left ventricle (LV)  
- Left ventricular assist device (LVAD)  
- Left ventricular end‑diastolic volume (LVEDV)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular hypertrophy (LVH)  
- Guideline‑directed medical therapy (GDMT)

Page 7 Extracted Terms:
- Heart Failure (HF)  
- Structural heart disease  
- Cardiomyopathies  
- Stages of HF (Stage A, Stage B, Stage C, Stage D)  
- ACC/AHA stages of HF  
- New York Heart Association (NYHA) Classification  
- NYHA functional classes (I, II, III, IV)  
- Left Ventricular Ejection Fraction (LVEF)  
- HF with reduced ejection fraction (HFrEF)  
- HF with preserved ejection fraction (HFpEF)  
- Biomarkers (e.g., NT‑proBNP, other natriuretic peptides)  
- Elevated filling pressures  
- Mechanical circulatory support (MCS)  
- Myocardial infarction (MI)  
- Mitral regurgitation (MR)  
- Mitral valve (MV)  
- Mineralocorticoid receptor antagonist (MRA)  
- Non‑steroidal anti‑inflammatory drug (NSAID)  
- Nonsustained ventricular tachycardia (NSVT)  
- Renin‑angiotensin‑aldosterone system (RAAS)  
- RAAS inhibitors (RAASi)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Transcatheter mitral edge‑to‑edge repair (TEER)  
- Transthoracic echocardiogram (TTE)  
- Ventricular arrhythmia (VA)  
- Ventricular fibrillation (VF)  
- Ventricular tachycardia (VT)  
- Valvular heart disease (VHD)  
- Right atrial (RA)  
- Right ventricular (RV)  
- Pulmonary artery (PA)  
- Pulmonary capillary wedge pressure (PCWP)  
- Oxygen consumption/oxygen uptake (VO₂)  
- Sudden cardiac death (SCD)  
- Quality‑adjusted life year (QALY)  
- Quality of life (QOL)  
- Randomized controlled trial (RCT)  
- Single photon emission CT (SPECT)  
- Positron emission tomography (PET)  
- Technetium‑pyrophosphate (¹⁰¹⁹Tc‑PYP)  
- Peroxisome proliferator‑activated receptor γ (PPAR‑γ)  
- Polyunsaturated fatty acid (PUFA)

Page 8 Extracted Terms:
- Coronary Artery Bypass Graft Surgery  
- Coronary Artery Revascularization  
- Percutaneous Coronary Intervention  
- Valvular Heart Disease  
- Hypertrophic Cardiomyopathy  
- Cardiovascular Disease  
- Atrial Fibrillation  
- High Blood Pressure (Hypertension)  
- Heart Failure  
- New Pharmacological Therapy for Heart Failure  
- Stable Ischemic Heart Disease  
- Atherosclerotic Cardiovascular Risk  
- Blood Cholesterol  
- Lifestyle Management to Reduce Cardiovascular Risk  
- Overweight and Obesity in Adults  
- Management of Blood Cholesterol  
- Assessment of Cardiovascular Risk  
- ST‑Elevation Myocardial Infarction  
- Device‑Based Therapy of Cardiac Rhythm Abnormalities  
- Cardiac Amyloidosis  
- Chest Pain  
- Primary Prevention of Cardiovascular Diseases  
- Diabetes Mellitus (cardiovascular risk)  
- Post–Cardiac Arrest Care  

Page 9 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mid‑range ejection fraction (HFmrEF)  
- Left ventricular ejection fraction (LVEF)  
- Natriuretic peptide  
- LV (left ventricular) filling pressures  
- Cardiac dysfunction  
- Clinical signs and symptoms of heart failure  
- Diagnostic specificity  
- Objective measures of cardiac dysfunction  
- Elevated natriuretic peptide levels  
- Exercise‑provoked (fluid‑challenge) LV pressure assessment  

Page 10 Extracted Terms:
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure – recovered ejection fraction (HF‑recovered EF)  
- Ejection fraction (EF) / Left ventricular ejection fraction (LVEF)  
- B-type natriuretic peptide (BNP) / Natriuretic peptides  
- Cardiac troponin (cardiac biomarkers of injury)  
- Left ventricular (LV) chamber dilatation  
- Ventricular systolic function  
- Ventricular diastolic function  
- Ventricular hypertrophy  
- Chamber enlargement  
- Wall motion abnormalities  
- Valvular heart disease  
- Structural heart disease  
- Increased filling pressures  
- Invasive hemodynamic measurements  
- Noninvasive imaging (e.g., Doppler echocardiography)  
- Doppler echocardiography  
- Guideline‑directed medical therapy (GDMT)  
- American College of Cardiology (ACC) – Heart failure stages  
- American Heart Association (AHA) – Heart failure stages  
- ACC/AHA stages of HF (Stages A, B, C, D)  
- Stage A: At risk for HF (risk factors, no symptoms)  
- Stage B: Pre‑HF (evidence of structural or functional abnormality without symptoms)  
- Stage C: Symptomatic HF (symptoms plus structural disease)  
- Stage D: Advanced HF (marked symptoms, recurrent hospitalizations)  
- Risk factors for HF  
- Hypertension  
- Atherosclerotic cardiovascular disease (CVD)  
- Diabetes mellitus  
- Metabolic syndrome  
- Obesity  
- Exposure to cardiotoxic agents  
- Genetic variants for cardiomyopathy  
- Positive family history of cardiomyopathy  
- Cardiac biomarkers of stretch or injury  
- Chronic kidney disease (CKD)  
- Pulmonary embolism (PE)  
- Myopericarditis  

These terms capture the key concepts, classifications, diagnostic measures, risk factors, and therapeutic categories related to heart disease as presented in the guideline text.

Page 11 Extracted Terms:
**Key terms related to heart disease**

- Heart failure (HF)  
- Left ventricular ejection fraction (LVEF)  
- HF with reduced EF (HFrEF)  
- HF with mildly reduced EF (HFmrEF)  
- HF with preserved EF (HFpEF)  
- HF with improved EF (HFimpEF)  
- Guideline‑directed medical therapy (GDMT)  
- Natriuretic peptides  
- E/e′ ratio (diastolic function parameter)  
- Left atrial size / left atrial volume index  
- Left ventricular (LV) mass / LV mass index  
- Pulmonary capillary wedge pressure  
- LV end‑diastolic pressure  
- Pulmonary artery (PA) pressures  
- Stroke volume  
- Cardiac output  
- H₂FPEF score (diagnostic composite score for HFpEF)  
- Obesity (as a risk factor)  
- Atrial fibrillation (AF)  
- Age >60 years  
- Antihypertensive medication burden (≥2 drugs)  
- PA systolic pressure >35 mm Hg  
- Diagnostic algorithm for HF classification  
- Structural heart disease  
- Diastolic dysfunction  
- Exercise stress testing (echocardiographic evaluation)  
- Invasive hemodynamic measurement (rest or exercise)  
- Stage C heart failure  
- Heart failure remission  
- Left ventricular (LV) structural/functional alterations  
- Echocardiographic diastolic parameters  
- Pulmonary artery systolic pressure  
- H₂FPEF score components (obesity, AF, age, antihypertensive meds, E/e′, PA pressure)

Page 12 Extracted Terms:
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure with improved ejection fraction (HFimpEF)  
- H2FPEF score  
- Left ventricular ejection fraction (LVEF)  
- Echocardiography / exercise echocardiogram  
- Cardiac catheterization  
- Dyspnea / exertional dyspnea  
- AHA/ACC/HFSA Heart Failure Guideline  
- European Society of Cardiology diagnostic algorithm  
- Obesity  
- Hypertension  
- Diabetes  
- Atrial fibrillation (AF)  
- Cardiac ischemia  
- Heart valve disease  
- Biomarker domain  
- Functional domain  
- Morphological domain  
- Diagnostic laboratory tests  
- Electrocardiogram (ECG)  
- Mortality from heart failure  
- Hospitalization for heart failure

Page 13 Extracted Terms:
- Heart failure (HF)  
- HFrEF (heart failure with reduced ejection fraction)  
- HFpEF (heart failure with preserved ejection fraction)  
- HFmrEF (heart failure with mildly reduced ejection fraction)  
- Ejection fraction (EF)  
- Left ventricular ejection fraction (LVEF)  
- B‑type natriuretic peptide (BNP)  
- N‑terminal pro‑B natriuretic peptide (NT‑proBNP)  
- Cardiomyopathy / cardiomyopathies  
- Cardiotoxicity  
- Hypertension  
- Obesity  
- Prediabetes  
- Diabetes  
- Atherosclerotic cardiovascular disease (CVD)  
- Mortality rate (age‑adjusted death rate)  
- Hospitalization rate (HF hospitalizations)  
- Incidence of heart failure  
- Diagnostic algorithm for HF  
- Electrocardiogram (ECG)  
- Racial/ethnic disparities in heart‑failure outcomes (e.g., non‑Hispanic Black, non‑Hispanic White, Hispanic, Asian/Pacific Islander)

Page 14 Extracted Terms:
- Heart failure (HF)  
- Stage A HF  
- Stage B HF  
- Ischemic heart disease  
- Myocardial infarction (MI)  
- Hypertension  
- Valvular heart disease (VHD)  
- Familial cardiomyopathies  
- Genetic cardiomyopathies  
- Amyloidosis  
- Cardiotoxicity (e.g., chemotherapy, cancer treatment)  
- Alcohol abuse  
- Cocaine abuse  
- Methamphetamine abuse  
- Tachycardia  
- Right‑ventricular (RV) pacing  
- Stress‑induced cardiomyopathy (Takotsubo)  
- Peripartum cardiomyopathy  
- Myocarditis  
- Autoimmune causes (e.g., rheumatologic disease)  
- Sarcoidosis  
- Iron overload  
- Hemochromatosis  
- Thyroid disease  
- Endocrine/metabolic conditions (diabetes, obesity, acromegaly, pheochromocytoma)  
- COVID‑19‑related myocardial injury  
- Cardiac imaging  
- Cardiac biomarkers  
- Myocardial injury  
- Cardiac maladaptive structural changes  
- Advanced HF  
- Clinical congestion  
- Jugular venous pressure (JVP)  
- Ejection fraction (EF)  
- HF staging  
- Cardiac rhythm‑related causes (tachycardia, premature ventricular contractions)  
- Chemotherapy cardiotoxicity  
- Rheumatologic or autoimmune disease  
- Infiltrative cardiac disease (amyloid, sarcoid, hemochromatosis)

Page 15 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Distention  
- Orthopnea  
- Bendopnea  
- Square‑wave response to the Valsalva maneuver  
- Leg edema  
- Clinical congestion  
- Diuretics (titration)  
- PARADIGM‑HF trial  
- LCZ696 (Sacubitril/Valsartan)  
- Enalapril  
- Kansas City Cardiomyopathy Questionnaire (KCCQ)  
- Natriuretic peptides  
- MAGGIC risk score  
- Mechanical Circulatory Support (MCS)  
- Cardiac transplantation  
- Advanced heart failure  
- Familial cardiomyopathy  
- Idiopathic dilated cardiomyopathy (DCM)  
- Genetic basis of cardiomyopathy  
- Muscular dystrophy  
- Pacemaker  
- Defibrillator  
- Heart transplant list  
- 3‑generation family pedigree  
- Gadolinium enhancement (cardiac MRI)  
- Major adverse cardiac events (MACE)  
- Cascade screening  
- Guideline‑directed medical therapy (GDMT)  
- Amyloid heart disease  
- Transthyretin amyloidosis  
- Light chain (AL) amyloidosis  
- Sarcoidosis‑related HF  
- Hemochromatosis‑related HF  
- Hypothyroidism‑related HF  
- Hyperthyroidism‑related HF  
- Acromegaly‑related HF  
- Connective tissue disease‑related HF  
- Tachycardia‑induced cardiomyopathy  
- High‑output heart failure  
- Arteriovenous fistula‑related HF  
- Myocardial ischemia  
- Pulmonary embolism  
- Systemic infection  
- Nonsteroidal anti‑inflammatory drugs (NSAIDs)  
- Chronic right‑ventricular (RV) pacing  
- Amiodarone (bradycardia, RV pacing)  
- Social determinants of health (housing stability, food security, transportation)

Page 16 Extracted Terms:
**Heart‑disease related terms extracted from the text**

- Heart failure (HF)  
- Ischemic cardiomyopathy  
- Cardiac amyloidosis  
- Sarcoidosis  
- Hemochromatosis  
- HIV‑associated cardiac disease  
- COVID‑19 related cardiac involvement  
- Chagas disease (cardiac form)  
- Hypothyroidism (cardiac effects)  
- Hyperthyroidism (cardiac effects)  
- Acromegaly (cardiac effects)  
- Connective‑tissue disorders (e.g., systemic sclerosis, systemic lupus)  
- Tachycardia‑induced cardiomyopathy  
- Takotsubo (stress‑induced) cardiomyopathy  
- Peripartum cardiomyopathy  
- Cancer‑therapy–related cardiotoxicity  
- Substance‑abuse–related cardiomyopathy  
- Atrial fibrillation (AF)  
- Acute coronary syndromes (ACS)  
- Valvular heart disease (VHD)  
- Left ventricular hypertrophy (LVH)  
- Right‑ventricular heart failure (RV HF)  
- Pulmonary embolism (pulmonary embolic–related cardiac strain)  
- Pulmonary arterial hypertension (pulmonary hypertension)  
- Obstructive sleep apnea (pulmonary/ cardiac impact)  
- Severe pneumonia (cardiovascular comorbidity)  
- Bacterial sepsis (cardiovascular impact)  
- Severe burns (cardiovascular impact)  
- Renal failure (cardiovascular comorbidity)  
- Anemia (cardiovascular impact)  
- Elevated natriuretic peptides (BNP/NT‑proBNP)

These terms encompass the principal cardiac conditions, comorbidities, and disease‑related syndromes referenced in the guideline text.

Page 17 Extracted Terms:
- B‑type natriuretic peptide (BNP)  
- N‑terminal prohormone of B‑type natriuretic peptide (NT‑proBNP)  
- Heart failure (HF)  
- Chronic heart failure  
- Hospitalized heart failure  
- Risk stratification in heart failure  
- Prognosis of heart failure  
- Left ventricular (LV) dysfunction  
- New‑onset heart failure  
- Predictive biomarkers for heart failure  
- Natriuretic peptide biomarkers  
- Cardiovascular disease (CVD)  
- Cardiovascular specialist  
- Team‑based heart‑failure care  
- Prevention of heart failure  
- Screening for heart failure (STOP‑HF)  
- Renin‑angiotensin‑aldosterone system (RAAS) antagonists  
- Beta blockers  
- Acute decompensated heart failure  
- Cardiac events  
- All‑cause mortality (in heart failure context)  
- Cardiovascular death  
- Major cardiovascular events  
- Post‑discharge prognosis  
- Readmission for heart failure  
- Echocardiography (for LV assessment)  
- Healthy lifestyle behaviors (in heart‑failure management)  
- Glycemic control (in diabetic patients with elevated NT‑proBNP)  
- Blood pressure/Hypertension (risk factor for HF)  
- Diabetes mellitus (risk factor for HF)  
- Vascular disease (risk factor for HF)  
- Obesity (reduces BNP/NT‑proBNP levels, impacting HF diagnosis)  
- Oxidative stress biomarkers (related to heart failure prognosis)  
- Inflammation biomarkers (related to heart failure prognosis)  
- Matrix remodeling biomarkers (related to heart failure prognosis)  

*(All terms are extracted or inferred from the guideline text and are central to heart‑disease evaluation, diagnosis, risk stratification, and management.)*

Page 18 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

1. BNP  
2. NT‑proBNP  
3. Heart failure (HF)  
4. Genetic cardiomyopathy  
5. Inherited cardiomyopathies  
6. Dilated cardiomyopathy (DCM)  
7. Left ventricular (LV) hypertrophy  
8. LV non‑compaction  
9. Right ventricular (RV) thinning/fatty replacement  
10. 12‑lead ECG findings (high/low voltage, conduction abnormalities, repolarization changes)  
11. Long QT syndrome  
12. Brugada syndrome  
13. Nonsustained ventricular tachycardia (NSVT)  
14. Premature ventricular contraction (PVC)  
15. Sustained ventricular tachycardia/fibrillation  
16. Implantable cardioverter‑defibrillator (ICD)  
17. Sudden death (primary prevention)  
18. Atrial fibrillation (AF) – early‑onset, “lone” AF  
19. Conduction disease (early onset)  
20. Pacemaker implantation (before age 65)  
21. Coronary artery disease (CAD)  
22. Genetic screening / testing  
23. Genetic counseling  
24. Guideline‑directed medical therapy (GDMT)  
25. Exercise limitation (for hypertrophic cardiomyopathy)  
26. Skeletal myopathy  
27. Neuropathy  
28. Cutaneous stigmata  
29. Dysmorphic features  
30. Mental retardation  
31. Congenital deafness  
32. Neurofibromatosis  
33. Renal failure with neuropathy  
34. Systemic syndromes associated with cardiomyopathy (e.g., limb‑girdle dystrophy, Duchenne/Becker muscular dystrophy, Emory‑Dreifuss)  
35. Cardiac morphology  
36. Family history (3‑generation pedigree)  
37. ECG conduction and repolarization abnormalities  
38. Defibrillator for primary prevention of sudden death  
39. Periodic echocardiographic and electrocardiographic screening for relatives  
40. Phenotype–genotype correlation in cardiomyopathy  

These terms capture the primary heart‑disease concepts, diagnostic markers, therapeutic interventions, and genetic considerations discussed in the guideline excerpt.

Page 19 Extracted Terms:
**Key terms related to heart disease**

- Heart failure (HF)  
- Acute decompensated heart failure  
- New‑onset heart failure  
- Dilated cardiomyopathy (DCM)  
- Restrictive cardiomyopathy  
- Hypertrophic cardiomyopathy  
- Peripartum cardiomyopathy  
- Alcoholic cardiomyopathy  
- Arrhythmogenic cardiomyopathy  
- Arrhythmogenic right‑ventricular cardiomyopathy (ARVC)  
- Conduction block  
- Atrial arrhythmias (e.g., atrial fibrillation)  
- Ventricular arrhythmias  
- Sudden cardiac death  
- Implantable cardioverter‑defibrillator (ICD)  
- Left ventricular ejection fraction (LVEF)  
- Transthoracic echocardiography (TTE)  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiac computed tomography (CT)  
- Radionuclide imaging  
- Single‑photon emission computed tomography (SPECT)  
- Positron emission tomography (PET)  
- Coronary artery disease (CAD)  
- Coronary revascularization (PCI/CABG)  
- Non‑invasive stress imaging  
- Ischemic heart disease  
- Left ventricular remodeling  
- Clinical guideline‑recommended therapy (GDMT)  
- Chest X‑ray (cardiac size, pulmonary congestion)  
- Cardiac imaging (diagnostic and serial assessment)  
- Genetic variants in titin (TTN)  
- Genetic variants in lamin A/C  
- Desmosomal protein mutations (e.g., PKP2, DSG2)  
- Filamin‑C mutations  
- Fabry’s disease cardiomyopathy  
- Enzyme replacement therapy (agalsidase β)  
- Migalastat (small‑molecule therapy for Fabry)  
- Primary prevention ICD criteria (LVEF > 0.35, <3 months of GDMT)  
- Exercise restriction in desmosomal cardiomyopathy  
- Ventricular remodeling acceleration (due to exercise)  
- Genetic confirmation of cardiomyopathy  
- Structural remodeling assessment  
- Valvular function evaluation  
- Echocardiogram adequacy  
- Functional and structural cardiac assessment  
- LVEF measurement in various modalities (echo, CMR, CT, radionuclide)

Page 20 Extracted Terms:
**Key terms related to heart disease**

- Heart Failure (HF)  
- Chest X‑ray  
- Cardiomegaly  
- Pulmonary venous congestion  
- Interstitial edema  
- Alveolar edema  
- Transthoracic Echocardiography (TTE)  
- Echocardiography  
- Myocardium (myocardial structure/function)  
- Heart valves  
- Pericardium  
- Left Ventricular Ejection Fraction (LVEF)  
- Ventricular dimensions  
- Ventricular volumes  
- Chamber geometry  
- Regional wall motion  
- Right Ventricular (RV) size  
- Right Ventricular function  
- Atrial size  
- Diastolic function  
- Left Ventricular filling  
- Left atrial pressure  
- Tricuspid valve regurgitant gradient  
- Inferior vena cava (IVC) diameter  
- Systolic pulmonary artery pressure (PA pressure)  
- Central venous pressure (CVP)  
- Global longitudinal strain (GLS)  
- Subclinical LV systolic dysfunction  
- Point‑of‑care cardiac ultrasound  
- Serial echocardiograms  
- Structural remodeling  
- Valvular function  
- Revascularization  
- Device therapies (e.g., pacemakers, ICD, CRT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Cardiac Resynchronization Therapy (CRT)  
- Left Ventricular (LV) systolic dysfunction  
- Chronic tachycardia  
- Thyroid disease (as HF precipitant)  
- Dilated cardiomyopathy  
- Peripartum cardiomyopathy  
- Myocarditis  
- Systemic inflammatory responses  
- Chemotherapy‑associated cardiotoxicity  
- Cardiac Magnetic Resonance (CMR)  
- Left ventricular mass  
- Cardiac volumes  
- Electrocardiographic‑gated cardiac CT  
- Radionuclide ventriculography (RVG)  
- Late Gadolinium Enhancement (LGE)  
- Myocardial fibrosis  
- Acute Myocardial Infarction (MI)  
- Chronic Myocardial Infarction (MI)  
- Coronary Artery Disease (CAD)  
- Infiltrative cardiomyopathies  
- Sarcoidosis  
- Fabry disease  
- Chagas disease  
- Noncompaction cardiomyopathy  
- Iron overload  
- Amyloidosis  
- T1 mapping  
- T2 mapping  
- Myocardial strain imaging  


Page 21 Extracted Terms:
Heart failure (HF)  
Coronary artery disease (CAD)  
Myocardial ischemia  
Revascularization, coronary revascularization  
Endomyocardial biopsy  
Right heart catheterization  
Invasive hemodynamic monitoring  
Noninvasive stress imaging  
Echocardiography  
Nuclear scintigraphy  
SPECT (single‑photon emission computed tomography)  
CMR (cardiac magnetic resonance imaging)  
PET (positron emission tomography)  
Viability imaging  
Myocardial viability  
STICH trial (Surgical Treatment for Ischemic Heart Failure)  
Cardiogenic shock  
Nonischemic cardiomyopathy  
Ischemic cardiomyopathy  
Obstructive CAD  
Amyloidosis  
Light‑chain (AL) amyloidosis  
Transthyretin amyloidosis (ATTR)  
Myocarditis  
Giant cell myocarditis  
Cardiac rejection  
Interstitial space characteristics  
Extracellular volume fraction  
Delayed hyperenhancement  
Cardiac infiltration (myocardial)

Page 22 Extracted Terms:
- Heart Failure (HF)  
- Acute heart failure (acute HF)  
- Right‑heart catheterization  
- Pulmonary artery (PA) catheterization  
- PA catheter monitoring  
- Hemodynamic evaluation/monitoring  
- ESCAPE trial  
- NYHA class III heart failure  
- NYHA class II–IV heart failure  
- Natriuretic peptide levels  
- Guideline‑directed medical therapy (GDMT)  
- CardioMEMS implantable PA pressure sensor  
- CHAMPION trial  
- GUIDE‑HF study  
- Implanted electronic devices (ICDs, CRT‑Ds)  
- Remote monitoring / telemonitoring  
- Wearables (remote monitoring devices)  
- Cardiac tamponade  
- Perforation (of myocardium)  
- Thrombus formation  
- Fluid status  
- Perfusion  
- Pulmonary vascular resistance  
- Systemic vascular resistance  
- Systolic blood pressure (SBP)  
- Renal function  
- Pulmonary capillary wedge pressure  
- Left ventricular ejection fraction (LVEF)  
- Beta‑blockers  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARBs)  
- Vasoactive agents  
- Invasive hemodynamic measurements  
- Endomyocardial biopsy (risk)  
- Clinical guidelines (AHA/ACC/HFSA)

Page 23 Extracted Terms:
- Heart failure (HF)  
- CardioMEMS device  
- CardioMEMS implantation and monitoring  
- Cardiopulmonary exercise testing (CPET)  
- NYHA functional classification (I–IV)  
- Left ventricular assist device (LVAD)  
- Heart transplantation  
- Dysphnea (dyspnea)  
- 6‑minute walk test  
- Peak VO₂ (peak oxygen consumption/uptake)  
- Peak VO₂ ≤ 14 mL/kg/min (transplant cutoff)  
- Peak VO₂ ≤ 12 mL/kg/min with beta‑blocker therapy (transplant cutoff)  
- Beta‑blockers  
- Survival (mortality, 1‑ and 2‑year survival)  
- Quality‑adjusted life year (QALY)  
- Cost‑effectiveness  
- Economic value of CardioMEMS  
- Cost estimates  
- Model duration  
- Quality of life (QOL) data  
- GUIDE‑HF trial  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- Heart Failure Society of America (HFSA)  
- Clinical benefit  
- Exercise intolerance  
- Functional capacity  
- Advanced treatments (e.g., LVAD, heart transplant)  
- Prognosis in HF  
- Clinical guidelines  
- Functional impairment  
- Exercise testing as a standardized, reliable measure  
- Clinical documentation of NYHA class  
- Candidate selection for drug/device therapy  
- Treatment eligibility criteria  
- Functional limitation grading  
- Reproducibility issues with NYHA classification  
- Risk stratification using CPET variables  

These terms capture the key heart‑disease–related concepts, diagnostics, therapies, and outcomes discussed in the guideline excerpt.

Page 24 Extracted Terms:
- AHA/ACC/HFSA Heart Failure Guideline  
- NYHA class III  
- NYHA class IV  
- 3‑year survival free of heart transplant  
- Dyspnea  
- Cardiopulmonary Exercise Test (CPET)  
- Treadmill exercise test  
- Stationary bicycle exercise test  
- Ventilatory gas exchange measurements  
- Oxygen uptake (VO₂)  
- Carbon dioxide output  
- Ventilation  
- Exercise capacity  
- Cardiopulmonary responses  
- Metabolic abnormalities  
- Deconditioning  
- HF Risk Scoring  
- Multivariable risk scores  
- Mortality  
- Hospitalization  
- Readmission for heart failure  
- Incident heart failure (HF)  
- Advanced heart failure therapies  
- Biomarker testing  
- Risk stratification  
- Seattle Heart Failure Model  
- Heart Failure Survival Score  
- MAGGIC (Meta‑analysis Global Group in Chronic Heart Failure)  
- CHARM Risk Score (Candesartan in Heart failure‑Assessed Reduction in Mortality and Morbidity)  
- CORONA Risk Score (Controlled Rosuvastatin Multinational Trial in Heart Failure)  
- PARADIGM‑HF  
- HF‑ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training)  
- GUIDE‑IT (Guiding Evidence‑Based Therapy Using Biomarker‑Intensified Treatment)  
- I‑PRESERVE Score (Irbesartan in Heart Failure with Preserved Ejection Fraction Study)  
- TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist)  
- ADHERE Classification (Acute Decompensated Heart Failure National Registry)  
- Regression Tree (CART) Model  
- AHA Get With The Guidelines Score  
- EFFECT Risk Score (Enhanced Feedback for Effective Cardiac Treatment)  
- ESCAPE Risk Model (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness)  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- HF (heart failure)  
- HFpEF (heart failure with preserved ejection fraction)  
- HFrEF (heart failure with reduced ejection fraction)  
- ARIC (Atherosclerosis Risk in Communities)  

These terms capture the key concepts related to heart disease as presented in the excerpt.

Page 25 Extracted Terms:
- Heart failure (HF)  
- Systolic heart failure (HFrEF)  
- Diastolic heart failure (HFpEF)  
- Ejection fraction (EF)  
- Left ventricular (LV) dysfunction  
- LV systolic dysfunction  
- LV diastolic dysfunction  
- Seattle Heart Failure Model  
- Heart Failure Survival Score  
- MAGGIC score  
- Multivariate risk scores  
- Natriuretic peptide biomarker  
- B-type natriuretic peptide (BNP)  
- N-terminal pro-BNP (NT‑proBNP)  
- Sodium‑glucose co‑transporter‑2 inhibitors (SGLT2i)  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Type 2 diabetes mellitus (T2DM)  
- Cardiovascular disease (CVD)  
- High cardiovascular risk  
- Smoking cessation  
- Obesity / weight control  
- Regular physical activity  
- Healthy dietary patterns  
- Lifestyle modifications  
- Primary prevention  
- Secondary prevention  
- Guideline‑directed medical therapy (GDMT)  
- AHA/ACC heart failure guideline  
- HFSA (Heart Failure Society of America)  
- Clinical risk prediction models  
- Collaborative care / team‑based care  
- Cardiovascular specialist  
- SPRINT trial  


Page 26 Extracted Terms:
- Heart Failure (HF)  
- Left Ventricular Systolic Dysfunction  
- Left Ventricular Ejection Fraction (LVEF)  
- B-type Natriuretic Peptide (BNP) Testing  
- St Vincent’s Screening to Prevent Heart Failure (STOP-HF)  
- Angiotensin‑Converting Enzyme Inhibitor (ACEi)  
- Angiotensin Receptor Blocker (ARB)  
- Sodium‑Glucose Cotransporter‑2 Inhibitor (SGLT2i)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Myocardial Infarction (MI)  
- Cardiovascular Disease (CVD)  
- Hypertension  
- Diabetes  
- Vascular Disease  
- Pre‑HF (Stage B)  
- Risk Stage A (Patients at Risk of HF)  
- Blood Pressure (BP)  
- Mediterranean Diet  
- DASH Diet (Dietary Approaches to Stop Hypertension)  
- Plant‑Based Diet  
- Whole‑Grain Diet  
- AHA/ACC/HFSA Heart Failure Guideline  
- Class of Recommendation (COR)  
- Composite Endpoint  
- Asymptomatic LV Dysfunction  
- Healthy Dietary Patterns  

Page 27 Extracted Terms:
- Heart failure (HF)  
- Stage A HF  
- Stage B HF (pre‑HF)  
- Symptomatic HF  
- Asymptomatic LV systolic dysfunction  
- Asymptomatic LV diastolic dysfunction  
- Left ventricular ejection fraction (LVEF)  
- LVEF ≤ 40 %  
- LVEF ≤ 30 %  
- LVEF < 50 %  
- New‑onset myocardial infarction (MI)  
- Acute coronary syndrome (ACS)  
- NT‑proBNP  
- Renin–angiotensin–aldosterone system (RAAS) antagonists  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin II receptor blockers (ARB)  
- Beta‑blockers  
- Guideline‑directed medical therapy (GDMT)  
- Statins  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death (SCD)  
- NYHA class I  
- Thiazolidinediones  
- Nondihydropyridine calcium‑channel blockers  
- QRS duration  
- Diabetes mellitus  
- Obesity  
- Hypertension  
- Framingham Heart Failure Risk Score  
- Health ABC Heart Failure Score  
- ARIC Risk Score (Atherosclerosis Risk in Communities)  
- PCP‑HF (Pooled Cohort Equations to Prevent HF)  
- Electronic health records (EHR)  
- Machine learning in risk prediction  
- Cardiovascular events  
- Mortality reduction  
- Risk prediction models  
- Population‑based cohorts  
- Clinical practice guidelines (AHA/ACC/HFSA)

Page 28 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Stage B heart failure  
- Myocardial infarction (MI)  
- Acute MI / acute myocardial infarction  
- ST‑elevation myocardial infarction (STEMI)  
- Non–ST‑elevation acute coronary syndrome (NST‑ACS) / acute coronary syndrome (ACS)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular dysfunction / LV dysfunction / left ventricular systolic dysfunction  
- Maladaptive cardiac remodeling  
- Pulmonary congestion  
- Mineralocorticoid receptor antagonist (MRA)  
- Angiotensin‑receptor‑neprilysin inhibitor (ARNi) – e.g., sacubitril/valsartan  
- Angiotensin‑converting enzyme inhibitor (ACEi) – e.g., ramipril, enalapril, captopril  
- Angiotensin‑II receptor blocker (ARB) – e.g., valsartan, losartan  
- Beta‑blocker – e.g., carvedilol, other β‑adrenergic antagonists  
- Statin therapy / statins  
- Guideline‑directed medical therapy (GDMT)  
- Coronary revascularization (percutaneous coronary intervention, PCI)  
- Coronary artery bypass graft surgery (CABG)  
- Valvular heart disease – valve replacement or repair for significant stenosis or regurgitation  
- Congenital heart disease (CHD)  
- Clinical trials / randomized controlled trials (RCTs) – e.g., SOLVD, VALIANT, OPTIMAAL, PARADISE‑MI  
- Guidelines – AHA/ACC/HFSA, ACCF/AHA, ACC/AHA/SCAI, ACC/AHA/STI, etc.  
- Cardiovascular disease (CVD) / cardiovascular risk  
- Angioedema (as a drug‑related adverse effect)

Page 29 Extracted Terms:
- Framingham studies  
- Left ventricular ejection fraction (LVEF)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Sudden cardiac death (SCD)  
- Myocardial infarction (MI)  
- Implantable cardioverter‑defibrillator (ICD)  
- Beta‑blockers  
- Angiotensin‑converting‑enzyme inhibitor (enalapril)  
- Thiazolidinediones (pioglitazone, rosiglitazone)  
- Fluid retention / edema  
- New York Heart Association (NYHA) class I‑II  
- Nondihydropyridine calcium‑channel blockers (diltiazem, verapamil)  
- Non‑pharmacologic interventions  
- Self‑care support for heart failure  
- Multidisciplinary care teams  
- Guideline‑directed medical therapy (GDMT)  
- Vaccination against respiratory illnesses  
- Depression (as a risk factor for poor self‑care)  
- Social isolation (as a risk factor for poor self‑care)  
- Frailty (as a risk factor for poor self‑care)  
- Low health literacy (as a risk factor for poor self‑care)

Page 30 Extracted Terms:
Heart failure (HF)  
Heart failure with reduced ejection fraction (HFrEF)  
HF hospitalization  
All‑cause mortality  
All‑cause readmission  
Cardiac death  
Self‑care  
Multidisciplinary team follow‑up  
Case management  
Pharmacist involvement  
Multidisciplinary interventions  
Medication adherence  
Structured telephone support  
Mobile‑health–delivered educational interventions  
Transitional‑care services program  
Angiotensin‑converting enzyme inhibitor (ACEi)  
Angiotensin receptor blocker (ARB)  
Angiotensin receptor‑neprilysin inhibitor (ARNi)  
Cardiac resynchronization therapy (CRT)  
Guideline‑directed medical therapy (GDMT)  
Implantable cardioverter‑defibrillator (ICD)  
Hydralazine and isosorbide dinitrate (hydral‑nitrates)  
Mechanical circulatory support (MCS)  
Left ventricular ejection fraction (LVEF)  
Mineralocorticoid receptor antagonist (MRA)  
Normal sinus rhythm (NSR)  
New York Heart Association (NYHA)  
Sodium‑glucose cotransporter‑2 inhibitor (SGLT2i)  
Left bundle branch block (LBBB)

Page 31 Extracted Terms:
**Key terms related to heart disease**

- Heart Failure (HF)  
- HFrEF (Heart Failure with reduced Ejection Fraction)  
- HFpEF (Heart Failure with preserved Ejection Fraction)  
- NYHA functional class  
- Constrictive/Constricted symptoms (symptoms of congestion)  
- Sodium restriction / Dietary sodium restriction  
- DASH diet (Dietary Approaches to Stop Hypertension)  
- Leg edema  
- Weight/fluid overload  
- Congestion  
- Diuretic use  
- Hospitalization / Hospitalisations  
- Rehospitalization  
- Mortality  
- All‑cause mortality  
- Cardiovascular mortality  
- Adverse cardiovascular events  
- Influenza vaccination  
- Pneumococcal vaccination  
- COVID‑19 vaccination (SARS‑CoV‑2)  
- Self‑care education / Self‑care  
- Depression (as a risk factor)  
- Social isolation  
- Frailty  
- Health literacy / Health numeracy  
- Nutritional adequacy  
- Macronutrient intake  
- Micronutrient intake  
- Iron supplementation  
- Thiamine supplementation  
- Zinc supplementation  
- Vitamin D supplementation  
- Multivitamin supplementation  
- Registered dietitian / Nurse‑coached dietetic intervention  
- Clinical outcomes  
- Clinical benefit / Clinical stability  
- Prospective Comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM‑HF)  
- Cardiovascular Health Study  
- Composite of mortality and cardiovascular hospitalizations  

(Note: The list prioritizes terminology directly associated with heart disease, its management, outcomes, and related interventions.)

Page 32 Extracted Terms:
- Heart Failure (HF)  
- Stage C Heart Failure  
- Cardiac Rehabilitation  
- Exercise Training / Exercise Prescription  
- Physical Activity  
- Functional Status  
- Exercise Performance  
- Quality of Life (QOL)  
- B‑type Natriuretic Peptide (BNP)  
- Sodium Intake / Dietary Sodium  
- Urinary Sodium  
- HF Self‑Care  
- AHA/ACC/HFSA Heart Failure Guideline (contextual reference)

Page 33 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Cardiac Rehabilitation  
- Exercise Training (supervised, graded)  
- Functional Capacity  
- Exercise Performance / Tolerance  
- Quality of Life (QoL)  
- Cardiovascular (CVD) Mortality  
- Hospitalization (all‑cause, HF‑specific)  
- NYHA Class II & III  
- Left Ventricular Ejection Fraction (LVEF) ≤ 35%  
- Diuretics  
  - Loop Diuretics (bumetanide, furosemide, torsemide)  
  - Thiazide Diuretics (metolazone, chlorthalidone, hydrochlorothiazide)  
  - Potassium‑sparing Diuretics (spironolactone)  
- Congestion  
- Fluid Retention / Edema  
- Electrolyte Abnormalities  
- Endothelial Function  
- Catecholamine Spillover  
- Peripheral Oxygen Extraction  
- Peak Oxygen Consumption (VO₂ peak)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Mineralocorticoid Receptor Antagonists (MRAs)  
- Vasopressin Antagonists  
- Hyponatremia  
- Loop of Henle  
- Distal Convoluting Tubule  
- Collecting Duct  
- Clinical Evidence of Fluid Retention  
- Euvolemia


Page 34 Extracted Terms:
**Key heart‑disease terms identified in the text**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- New York Heart Association (NYHA) class II–III  
- Congestion / volume overload  
- Serum sodium  
- Urinary sodium excretion  
- Physical signs of fluid retention  
- Quality of life (QOL)  
- Exercise tolerance  
- Hospitalization for HF  
- All‑cause 30‑day mortality  
- Diuretics  
- Loop diuretics  
- Furosemide  
- Bumetanide  
- Torsemide  
- Metolazone (thiazide‑like diuretic)  
- Thiazide diuretics (chlorthiazide, chlorthalidone, hydrochlorothiazide, indapamide)  
- Diuretic resistance  
- Intravenous diuretics (bolus or continuous infusion)  
- Combination diuretic therapy  
- Renin–angiotensin system inhibition  
- Angiotensin‑converting‑enzyme inhibitor (ACEi)  
- Angiotensin‑II receptor blocker (ARB)  
- Angiotensin‑receptor neprilysin inhibitor (ARNi)  
- DOSE trial (Diuretic Optimization Strategies Evaluation)  
- OPTIMIZE‑HF registry  
- Oral bioavailability  
- Hypokalemia  
- Hyponatremia  
- Worsening renal function  
- Cough (ACEi side effect)  
- Angioedema (contraindication to ACEi/ARNi)  
- High‐value economic therapy  
- Safety and harm statements (e.g., ARNi/ACEi overlap within 36 h)

Page 35 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- New York Heart Association (NYHA) Class II symptoms  
- New York Heart Association (NYHA) Class III symptoms  
- Angiotensin‑Converting Enzyme Inhibitor (ACEi)  
- Angiotensin‑Receptor Blocker (ARB)  
- Angiotensin‑Receptor Neprilysin Inhibitor (ARNi)  
- Sacubitril–valsartan (ARNi)  
- Enalapril (ACEi)  
- Natriuretic peptides (e.g., BNP, NT‑proBNP)  
- Bradykinin  
- Adrenomedullin  
- Vasoactive peptides  
- LV remodeling (left‑ventricular remodeling)  
- NT‑proBNP (biomarker)  
- Hypotension (symptomatic)  
- Angioedema  
- Renal function (renal insufficiency)  
- Hyperkalemia (serum potassium >5.0 mEq/L)  
- Hospitalization for heart failure  
- Acute decompensated heart failure  
- Chronic symptomatic heart failure  
- PIONEER‑HF trial  
- TRANSITION trial  
- PARADIGM‑HF trial  
- PARADISE‑MI trial  
- Cardiac death (cardiovascular death)  
- HF hospitalization (re‑hospitalization)  
- LVEF ≤ 40 % (left‑ventricular ejection fraction)  
- Pulmonary congestion  
- Coronary artery disease (CAD)  
- Diabetes mellitus (as a risk factor)  
- Myocardial infarction (MI)  
- Early post‑MI period  
- Hemodynamics  
- Mortality reduction  
- Morbidity reduction  
- Clinical deterioration (after abrupt ACEi withdrawal)  
- Symptomatic improvement  
- Clinical deterioration (after abrupt ACE inhibition withdrawal)  
- Symptom‑guided titration  
- Maximally tolerated doses (of ACEi/ARB/ARNi)  
- Clinical guidelines (AHA/ACC/HFSA)  
- Guideline‑specific trial endpoints  
- Prospective Randomized Controlled Trial (RCT)  
- Composite endpoint (cardiovascular death or HF hospitalization)  

These terms collectively capture the clinical entities, pharmacologic agents, biomarkers, therapeutic goals, and key trials referenced in the guideline excerpt.

Page 36 Extracted Terms:
- AHA/ACC/HFSA Heart Failure Guideline  
- Heart Failure (HF)  
- Heart Failure with reduced ejection fraction (HFrEF)  
- Chronic heart failure (HF)  
- Neurohormonal  
- Renin‑angiotensin system  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin‑receptor blocker (ARB)  
- Angiotensin‑receptor neprilysin inhibitor (ARNi)  
- Enalapril  
- Sacubitril‑valsartan (valsartan‑based ARNi)  
- Valsartan  
- Val-HeFT (Valsartan Heart Failure Trial)  
- ELITE (Evaluation of Losartan in the Elderly) study  
- SOLVD (Studies of Left Ventricular Dysfunction)  
- PARADIGM‑HF (Prospective Comparison of ARNI with ACE inhibitor in Heart Failure)  
- PIONEER‑HF (Prospective Study of ARNI in Acute Heart Failure)  
- Omapatrilat (neprilysin inhibitor/ACEi combination)  
- Neprilysin inhibitor  
- Bradykinin  
- Angioedema  
- Hypertension (arterial hypertension)  
- Low systemic blood pressure  
- Renal insufficiency  
- Serum potassium (hyper‑kalaemia)  
- LV dysfunction  
- LV remodeling  
- Hospitalization  
- Mortality  
- Cost‑effectiveness analysis  
- Quality‑adjusted life year (QALY)  
- Clinical trial outcomes  
- Economic value  
- Treatment cost per QALY  
- Guideline benchmarks (value thresholds)

Page 37 Extracted Terms:
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure (HF)  
- β‑blockers  
- Bisoprolol  
- Carvedilol  
- Sustained‑release metoprolol succinate  
- Mortality  
- Hospitalization  
- Left ventricular ejection fraction (LVEF)  
- Coronary artery disease (CAD)  
- Diabetes mellitus  
- Atrial fibrillation (AF)  
- Major cardiovascular events  
- β‑blocker dosing, sequencing, and uptitration  
- Mineralocorticoid receptor antagonists (MRAs)  
- Spironolactone  
- Eplerenone  
- Hyperkalemia  
- Life‑threatening hyperkalemia  
- Renal insufficiency  
- Estimated glomerular filtration rate (eGFR)  
- Serum potassium  
- NYHA class II‑IV symptoms  
- Sudden cardiac death (SCD)  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARB)  
- Bradykinin  
- Angioedema  



Page 38 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF)  
- Mineralocorticoid receptor antagonist (MRA)  
- Eplerenone  
- Spironolactone  
- Randomized Aldactone Evaluation Study (RALES)  
- Eplerenone Post‑Acute Myocardial Infarction Heart Failure Evaluation Study (EPHESUS)  
- Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‑HF)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Dapagliflozin  
- Empagliflozin  
- DAPA‑HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure)  
- EMPEROR‑Reduced trial (EMPagliflozin Outcomes Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction)  
- Hyperkalemia  
- Estimated glomerular filtration rate (eGFR)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin receptor blocker (ARB)  
- Angiotensin receptor‑neprilysin inhibitor (ARNi)  
- PARADIGM‑HF trial (Prospective Comparison of Angiotensin II Antagonist–Drug Interventions in the Management of Heart Failure)  
- PIONEER‑HF trial (Phase II/III study evaluating novel therapies in decompensated heart failure)  
- Potassium binders (patiromer, sodium zirconium cyclosilicate)  
- Cardiovascular mortality  
- Hospitalization for heart failure  
- Acute myocardial infarction (MI)  
- Type 2 diabetes mellitus  
- Quality‑adjusted life year (QALY)  
- Economic value of therapy  
- AHA/ACC/HFSA Heart Failure Guideline  

These terms capture the key concepts, therapies, trials, and clinical outcomes discussed in the guideline excerpt.

Page 39 Extracted Terms:
- Heart Failure with Reduced Ejection Fraction (HFrEF)
- Left Ventricle Ejection Fraction (LVEF ≤ 40%)
- New York Heart Association (NYHA) Functional Class II, III, IV
- Natriuretic peptides (BNP/NT‑proBNP)
- SGLT2 inhibitors (SGLT2i)
- Dapagliflozin
- Empagliflozin
- Sotagliflozin
- Hydralazine
- Isosorbide dinitrate
- Composite endpoint of cardiovascular death or heart‑failure hospitalization
- Cardiovascular death
- All‑cause mortality
- Heart‑failure (HF) hospitalization
- eGFR (estimated glomerular filtration rate)
- Chronic kidney disease (CKD) / renal insufficiency
- Euglycemic ketoacidosis
- Genital infections
- Soft‑tissue infections
- Volume depletion
- DAPA‑HF trial
- EMPEROR‑Reduced trial
- SOLOIST‑WHF trial
- V‑HeFT I (Vasodilator Heart Failure Trial)
- A‑HeFT (African‑American Heart Failure Trial)
- Guideline‑Directed Medical Therapy (GDMT)
- Angiotensin‑converting enzyme inhibitor (ACEi)
- Angiotensin receptor blocker (ARB)
- Beta‑blocker
- Mineralocorticoid receptor antagonist (MRA)
- Angiotensin receptor‑neprilysin inhibitor (ARNi)
- Quality‑Adjusted Life Year (QALY)
- Cost‑effectiveness analysis
- African American population (race‑specific therapy)
- Heart‑failure biomarker (Natriuretic peptides)
- Heart‑failure morbidity and mortality
- Heart‑failure symptom improvement



Page 40 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF)  
- Vasodilator therapy (hydralazine)  
- Isosorbide dinitrate (ISO)  
- Hydralazine‑isosorbide dinitrate combination  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin receptor blocker (ARB)  
- Angiotensin receptor‑neprilysin inhibitor (ARNi)  
- Beta‑blocker  
- Mineralocorticoid receptor antagonist (MRA)  
- Renin‑angiotensin‑aldosterone system inhibitor (RAASi)  
- Digoxin  
- Diuretic  
- Renal insufficiency (as risk factor for HF)  
- Hyperkalemia (serum potassium ≥ 5.5 mEq/L)  
- Potassium binders (patiromer, sodium zirconium cyclosilicate)  
- Omega‑3 polyunsaturated fatty acids (omega‑3 PUFA)  
- Eicosapentaenoic acid (EPA)  
- Docosahexaenoic acid (DHA)  
- GISSI‑HF trial  
- REDUCE‑IT trial  
- Mortality (all‑cause, cardiovascular, sudden cardiac death)  
- Cardiovascular events (fatal and non‑fatal, hospitalizations)  
- Cardiovascular disease (CVD)  
- Heart failure class II‑IV symptoms  
- Cardiovascular hospitalization  

These terms represent the core heart‑disease concepts discussed in the guideline text.

Page 41 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Chronic Heart Failure (CHF)  
- Hyperkalemia  
- Renin‑Angiotensin‑Aldosterone System Inhibitors (RAASi)  
- Patiromer (potassium binder)  
- Sodium Zirconium Cyclosilicate (SZC)  
- PEARL‑HF trial  
- HARMONIZE trial  
- Warfarin  
- Aspirin  
- Clopidogrel  
- Rivaroxaban  
- Antithrombotic therapy  
- Anticoagulation  
- Thromboembolic events  
- Venous Thromboembolism (VTE)  
- Atrial Fibrillation (AF)  
- Cardioembolic source  
- Myocardial Infarction (MI)  
- Stroke (ischemic, intracerebral hemorrhage)  
- Non‑fatal MI  
- Non‑fatal stroke  
- Coronary revascularization  
- Unstable Angina  
- Omega‑3 Polyunsaturated Fatty Acids (PUFA)  
- Eicosapentaenoic Acid (EPA)  
- Dipeptidyl Peptidase‑4 (DPP‑4) Inhibitors (saxagliptin, alogliptin)  
- Thiazolidinediones (TZDs)  
- Calcium Channel Blockers (dihydropyridine, nondihydropyridine)  
- Class IC Antiarrhythmic Medications  
- Dronedarone  
- Non‑steroidal Anti‑Inflammatory Drugs (NSAIDs)  
- Vitamins and Nutritional Supplements  
- Hormonal Therapy  
- Ventricular Arrhythmias  
- Mortality  
- Cardiovascular Death  
- Cardio‑renal Benefit  
- Fecal Excretion (potassium)

Page 42 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Nonischemic cardiomyopathy  
- LV afterload  
- Calcium channel blockers  
- Second‑generation dihydropyridine calcium channel blockers  
- Amlodipine  
- Felodipine  
- Diltiazem (nondihydropyridine calcium channel blocker)  
- Verapamil (nondihydropyridine calcium channel blocker)  
- PRAISE‑1 (Prospective Randomized Amlodipine Survival Evaluation‑1)  
- PRAISE‑2 (Prospective Randomized Amlodipine Survival Evaluation‑2)  
- Coenzyme Q₁₀  
- Q‑SYMBIO (Coenzyme Q₁₀ as adjunctive treatment of chronic heart failure)  
- NYHA functional classification  
- Major adverse cardiovascular events (MACE)  
- Brain‑natriuretic peptide (BNP)  
- Guideline‑directed medical therapy (GDMT)  
- Vitamin D  
- Thiamine  
- Carnitine  
- Taurine  
- Vitamin E  
- Testosterone therapy  
- Growth hormone therapy  
- Thyroid hormone therapy  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Cyclo‑oxygenase (COX) inhibitors  
- COX‑2 selective inhibitors  
- Thiazolidinediones  
- Saxagliptin  
- Alogliptin  
- Flecainide  
- Disopyramide  
- Sotalol  
- Dronedarone  
- Alpha‑1 adrenergic blockers  
- Doxazosin  
- Nifedipine  

Page 43 Extracted Terms:
**Key Terms Related to Heart Disease**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Cardiomyopathy  
- Acute myocardial infarction (MI)  
- Recurrent heart failure  
- Structural heart disease  
- Ventricular arrhythmias  
- Atrial‑ventricular arrhythmias (refractory)  
- Guideline‑directed medical therapy (GDMT)  
- Anti‑arrhythmic drug classes  
- Class IC anti‑arrhythmics (e.g., encainide, flecainide)  
- Class III anti‑arrhythmics (e.g., dronedarone, sotalol)  
- Class IA anti‑arrhythmics (e.g., quinidine)  
- Class IB anti‑arrhythmics (e.g., mexiletine)  
- Specific anti‑arrhythmic agents  
  - Diltiazem  
  - Encainide  
  - Flecainide  
  - Dronedarone  
  - Sotalol  
  - Amiodarone  
  - Dofetilide  
  - Quinidine  
  - Mexiletine  
- Systolic heart failure trials  
  - CAST (Cardiac Arrhythmia Suppression Trial)  
  - ANDROMEDA (Anti‑arrhythmic Trial with Dronedarone)  
  - SWORD (Survival With Oral D‑sotalol)  
- Thiazolidinediones (e.g., rosiglitazone, pioglitazone)  
- Peroxisome proliferator‑activated receptor‑γ (PPAR‑γ)  
- Sodium‑water retention in heart failure  
- Nitro‑sodic‑acid‑dependent peptides (DPP‑4) inhibitors  
  - Saxagliptin  
  - Alogliptin  
  - Sitagliptin  
  - Linagliptin  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Implantable cardioverter‑defibrillators (ICDs)  
- Hospitalization for heart failure  
- Cardiovascular mortality  
- All‑cause mortality reduction with GDMT  
- ACE inhibitors (ACEi)  
- Angiotensin receptor blockers (ARB)  
- Angiotensin receptor‑neprilysin inhibitors (ARNi)  
- β‑blockers  
- Diuretic therapy and sodium‑resorption suppression  
- Glycemic control agents affecting HF risk (metformin, insulin, sulfonylureas)  
- Fluid‑retention risk factors in diabetes treatment  
- Titration and uptitration of guideline‑directed therapy  

---

Page 44 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Ejection fraction (EF)  
- Angiotensin‑converting enzyme inhibitor (ACEi) – e.g., captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril  
- Angiotensin‑receptor blocker (ARB) – e.g., candesartan, losartan, valsartan  
- Angiotensin‑receptor neprilysin inhibitor (ARNi) – sacubitril‑valsartan  
- Beta‑blocker – e.g., bisoprolol, carvedilol, metoprolol succinate (CR/XL)  
- Mineralocorticoid‑receptor antagonist – e.g., spironolactone, eplerenone  
- Sodium‑glucose cotransporter‑2 inhibitor (SGLT2i) – e.g., dapagliflozin, empagliflozin  
- Isosorbide dinitrate  
- Hydralazine  
- Isosorbide dinitrate plus hydralazine (fixed‑dose combination)  
- Ivabradine (I‑channel inhibitor)  
- Vericiguat (soluble guanylate cyclase stimulator)  
- Digoxin (cardiac glycoside)  
- Clinical benefit / dose‑response relationship in heart failure therapies  
- Target dose vs. lower dose of HFrEF medications  



Page 45 Extracted Terms:
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Stage C Heart Failure  
- New York Heart Association (NYHA) Class II–III  
- Left Ventricular Ejection Fraction (LVEF) ≤ 35 %  
- Guideline‑Directed Medical Therapy (GDMT)  
- β‑blockers  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin Receptor Blockers (ARB)  
- Angiotensin Receptor Neprilysin Inhibitors (ARNi)  
- Sodium‑Glucose Cotransporter‑2 Inhibitors (SGLT2i)  
- Mineralocorticoid Receptor Antagonists (MRA)  
- Ivabradine  
- Hydralazine + Nitrate therapy  
- Cardiac Resynchronization Therapy (CRT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Heart Rate (≥ 70 bpm at rest)  
- Sinus Rhythm  
- Blood Pressure monitoring  
- Electrolyte monitoring  
- Renal function monitoring  
- Cardiovascular death  
- Heart Failure hospitalization  
- Relative Risk Reduction (RRR)  
- Number Needed to Treat (NNT)

Page 46 Extracted Terms:
**Key Heart Disease–Related Terms Extracted**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF) ≤ 35%  
- New York Heart Association (NYHA) class II–III  
- Hospitalization (HF hospitalization, HFH)  
- Cardiovascular death  
- Guideline‑directed medical therapy (GDMT)  
- Beta‑blocker therapy (optimal doses, uptitration)  
- Ivabradine therapy (targeting heart rate ≥ 70 bpm)  
- Digoxin (low dose initiation, serum concentration monitoring)  
- Renin‑angiotensin‑aldosterone system inhibitors (RAASi)  
- Mitral valve regurgitation (MR)  
- Normal sinus rhythm (NSR)  
- Shift trial (SHIFT) – a clinical trial on HFrEF  
- AHA/ACC/HFSA Heart Failure Guideline  
- Clinical outcomes: mortality, morbidity, QOL, exercise tolerance  
- Biomarkers: natriuretic peptide (NP)  
- Cardiac imaging metrics: left ventricular end‑systolic dimension (LVESD)  

These terms capture the most clinically and guideline‑relevant concepts related to heart disease found in the provided text.

Page 47 Extracted Terms:
- **Heart Failure (HF)**
- **Heart Failure with Reduced Ejection Fraction (HFrEF)**
- **Vericiguat**
- **Soluble Guanylate Cyclase (sGC) Stimulator**
- **Soluble Guanylyl Cyclase Stimulator**
- **GDMT (Guideline‑Directed Medical Therapy)**
- **Digoxin**
- **LVEF (Left Ventricular Ejection Fraction)**
- **NYHA Class (New York Heart Association Functional Classification)**
- **BNP (Brain Natriuretic Peptide)**
- **NT‑proBNP (N‑terminal pro B‑type Natriuretic Peptide)**
- **VICTORIA Trial**
- **ICD (Implantable Cardioverter‑Defibrillator)**
- **CRT (Cardiac Resynchronization Therapy)**
- **DCM (Dilated Cardiomyopathy)**
- **MI (Myocardial Infarction)**
- **SCD (Sudden Cardiac Death)**
- **LBBB (Left Bundle Branch Block)**
- **QRS duration**
- **Non‑LBBB pattern**
- **NT‑proBNP level ≥ 5314 pg/mL (high‑risk subgroup)**
- **SBP < 100 mm Hg (systolic blood pressure)**
- **eGFR < 15 mL/min/1.73 m² (estimated glomerular filtration rate)**
- **High‑value clinical interventions**

Page 48 Extracted Terms:
- LVEF  
- sinus rhythm  
- left bundle branch block (LBBB)  
- QRS duration  
- NYHA class  
- guideline‑directed medical therapy (GDMT)  
- cardiac resynchronization therapy (CRT)  
- atrial fibrillation (AF)  
- ventricular pacing  
- implantable cardioverter‑defibrillator (ICD)  
- sudden cardiac death (SCD)  
- ischemic cardiomyopathy  
- non‑ischemic cardiomyopathy  
- arrhythmogenic cardiomyopathy  
- heart failure (HF)  
- mortality  
- hospitalizations  
- quality of life (QOL)  
- non‑LBBB pattern  
- QRS duration <120 ms  
- QRS duration <150 ms  
- frailty (impacting survival <1 year)  
- resuscitated cardiac arrest  
- antiarrhythmics  
- defibrillators  
- trial names and acronyms:  
  - AVID (Antiarrhythmics versus Implantable Defibrillators trial)  
  - CASH (Cardiac Arrest Study Hamburg)  
  - CIDS (Canadian Implantable Defibrillator Studies)  
  - MADIT (Multicenter Automated Defibrillator Implantation Trial)  
  - MADIT‑II (Multicenter Automatic Defibrillator Implantation Trial II)  
  - MUSTT (Multicenter UnSustained Tachycardia Trial)  
  - DEFINT (Defibrillators in Non‑Ischemic Cardiomyopathy Treatment Evaluation)  
  - SCD‑HEFT (Sudden Cardiac Death in Heart Failure Trial)  
  - DANISH (Defibrillator Implantation in Patients with Non‑ischemic Systolic Heart Failure)  
- ICD implantation for primary prevention  
- CRT‑D (CRT with defibrillation)  
- ICD and CRT indications  
- survival benefit / cost‑effectiveness ratios (e.g., <$60,000 per year of life added)  
- life expectancy increase (>1.4 years)  
- coronary artery bypass graft (CABG) Patch trial (contrast with ICD benefit)

Page 49 Extracted Terms:
- Heart Failure (HF)  
- Congestive Heart Failure (CHF)  
- Left Ventricular Ejection Fraction (LVEF)  
- New York Heart Association (NYHA) class I–IV  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Cardiac Resynchronization Therapy (CRT)  
- CRT‑D (CRT with defibrillator)  
- CRT‑P (CRT pacemaker)  
- MADIT‑II trial  
- MADIT‑CRT trial  
- COMPANION trial  
- CARE‑HF trial  
- REVERSE trial  
- RAFT trial  
- HFrEF (Heart Failure with reduced Ejection Fraction)  
- Cardiomyopathy  
- Left Bundle Branch Block (LBBB / LBBB)  
- Right Ventricular (RV)  
- Left Ventricular (LV)  
- QRS duration  
- Atrial Fibrillation (AF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- 6‑minute walk test  
- Quality of Life (QOL)  
- Primary endpoint of death or hospitalization  
- Composite HF endpoint

Page 50 Extracted Terms:
- Cardiac Resynchronization Therapy (CRT)  
- Left Bundle Branch Block (LBBB)  
- Non‑Left Bundle Branch Block (non‑LBBB)  
- QRS duration & QRS width (>130 ms, >150 ms)  
- Left Ventricular Ejection Fraction (LVEF)  
- Biventricular pacing  
- Right Ventricular (RV) pacing  
- Ventricular pacing burden (>40 %)  
- Chronic heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- New York Heart Association (NYHA) functional classes I–IV  
- Atrial fibrillation (AF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Guideline‑directed medical therapy (GDMT)  
- Ischemic heart disease  
- Non‑ischemic cardiomyopathy  
- Cardiomyopathy (general)  
- Sudden cardiac death  
- Cardiac transplantation  
- Natriuretic peptide (NP)  
- Mitral valve (MV)  
- Mitral regurgitation (MR)  
- Pulmonary artery systolic pressure (PASP)  
- Normal sinus rhythm (NSR)  
- 6‑minute walk test  
- Left Ventricular End‑Systolic Dimension (LVESD)  
- Key CRT trials: COMPANION, MADIT‑CRT, REVERSE, BLOCK‑HF, CARE‑HF, RAFT, MUSTIC‑AF, SPARE, PAVE  
- Economic value indicators: cost per QALY, incremental cost‑effectiveness ratio (ICER)

Page 51 Extracted Terms:
- Heart Failure (HF)  
- HFrEF (Heart Failure with reduced Ejection Fraction)  
- HFpEF (Heart Failure with preserved Ejection Fraction)  
- Left Ventricular Ejection Fraction (LVEF)  
- New York Heart Association (NYHA) functional class III/IV  
- QRS duration (narrow QRS, <120 ms; 120–130 ms; non‑LBBB 120–149 ms)  
- Cardiac Resynchronization Therapy (CRT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Baroreceptor Stimulation (carotid artery)  
- Vagus Nerve Stimulation (VNS)  
- Spinal Cord Stimulation (SCS)  
- Left Bundle Branch Block (LBBB) pacing  
- His Bundle pacing  
- Cardiac Contractility Modulation (CCM)  
- Coronary Artery Disease (CAD)  
- Revascularization  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Left Ventricular (LV) dysfunction  
- Mechanical dyssynchrony (detected by echocardiography)  
- Mortality (all‑cause, cardiovascular, HF‑specific)  
- Hospitalization (all‑cause, cardiovascular, HF)  
- Quality of Life (QOL)  
- NT‑proBNP (biomarker for HF severity)

Page 52 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Left Ventricular (LV) Dysfunction  
- Left Ventricular Ejection Fraction (EF)  
- Ischemic Cardiomyopathy  
- Coronary Artery Bypass Grafting (CABG)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Left Ventricular End‑Systolic Dimension (LVESD)  
- Pulmonary Artery Systolic Pressure  
- Right Ventricular (RV) Failure  
- Pulmonary Hypertension  
- Valvular Heart Disease (VHD)  
- Severe Aortic Stenosis  
- Aortic Regurgitation  
- Mitral Regurgitation (MR) – secondary  
- Tricuspid Regurgitation (TR) – secondary  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Transcatheter Aortic Valve Replacement (TAVR)  
- TAVR UNLOAD Trial  
- Transcatheter Mitral Valve Edge‑to‑Edge Repair (TEER) – MitraClip  
- COAPT Trial  
- MITRA‑FR Trial  
- Surgical Ventricular Remodeling  
- LV Remodeling (proportionate vs. disproportionate MR)  
- Multidisciplinary Heart Failure Team  
- Cardiac Imaging (including transesophageal echocardiography)

Page 53 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Secondary mitral regurgitation (MR)  
- Guideline‑directed medical therapy (GDMT)  
- Renin–angiotensin‑aldosterone system (RAAS) inhibition  
- Beta‑blockers  
- Biventricular pacing (cardiac resynchronization therapy)  
- Sacubitril‑valsartan  
- Effective regurgitant area (ERO)  
- Regurgitant volume (RVol)  
- Regurgitant fraction (RF)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑systolic diameter (LVESD)  
- Pulmonary artery systolic pressure (PASP)  
- Atrial fibrillation (AF)  
- Coronary artery bypass graft (CABG)  
- New York Heart Association (NYHA) class  
- COAPT trial  
- Mitral valve (MV)  
- Left ventricle (LV)  
- Mitral valve replacement (MV replacement)  
- Annuloplasty repair  
- Cardiology (expertise in heart failure management)  
- Shared decision‑making (for valve intervention)

Page 54 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Left ventricular ejection fraction (LVEF)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Empagliflozin  
- β‑blockers (beta blockers)  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARB)  
- Angiotensin receptor‑neprilysin inhibitors (ARNi)  
- Mineralocorticoid receptor antagonists (MRAs)  
- Spironolactone  
- Natriuretic peptides (BNP, NT‑proBNP)  
- Cardio‑vascular mortality  
- Heart‑failure hospitalization  
- EmpEROR‑Preserved study  
- PARAGON‑HF study  
- BBmeta‑HF (beta‑blockers meta‑analysis)  
- eGFR (estimated glomerular filtration rate)  
- Quality of life (QOL)  
- Symptomatic heart failure  
- Post‑hoc analyses  
- Subgroup analyses  
- Composite endpoint (HF hospitalization or cardiovascular death)

Page 55 Extracted Terms:
**Key heart‑disease terms extracted from the text**

1. Heart failure (HF)  
2. Heart failure with reduced ejection fraction (HFrEF)  
3. Heart failure with mid‑range ejection fraction (HFmrEF)  
4. Heart failure with preserved ejection fraction (HFpEF)  
5. Left ventricular ejection fraction (LVEF)  
6. Left ventricular end‑diastolic volume (LVEDV)  
7. Natriuretic peptides (BNP, NT‑proBNP)  
8. Global cardiovascular health management therapy (GDMT)  
9. Candesartan (anthro‑study CHARM)  
10. Spirontolactone (TOPCAT)  
11. Aldosterone antagonist therapy  
12. Sodium–glucose cotransporter‑2 inhibitors (SGLT2i)  
13. Mineralocorticoid receptor antagonists (MRAs)  
14. Angiotensin‑receptor blocker (ARB)  
15. Angiotensin‑receptor neprilysin inhibitor (ARNi)  
16. Nitrates (pharmacologic therapy)  
17. Phosphodiesterase‑5 inhibitors  
18. Atrial fibrillation (AF) management  
19. Diuretics and decongestion strategies  
20. Coronary artery disease (CAD)  
21. Sarcoidosis  
22. Amyloidosis  
23. Kansas City Cardiomyopathy Questionnaire (KCCQ)  
24. Cardiocardiomyopathy relapse  
25. Cardiovascular death, cardiovascular mortality  
26. Heart‑failure hospitalization  
27. Reduced mortality in heart failure trials (CHA‑RM, TOPCAT)  
28. LVEF trajectories and monitoring  
29. Structural heart disease (Stage C HF)  
30. Relapse/recurrence of heart failure  
31. Blood pressure targets/management in HF  
32. Hypertension in HFpEF  

These terms capture the main cardiovascular conditions, therapeutic agents, clinical measures, and relevant research references discussed in the guideline excerpt.

Page 56 Extracted Terms:
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular ejection fraction (LVEF)  
- Natriuretic peptides (BNP, NT‑proBNP)  
- Diuretics  
- Amyloidosis (cardiac)  
- Hypertension  
- Diabetes mellitus  
- Obesity  
- Coronary artery disease (CAD)  
- Chronic kidney disease (CKD)  
- Atrial fibrillation (AF)  
- Blood pressure control / management  
- Renin–angiotensin–aldosterone system (RAAS) antagonists  
  - Angiotensin‑converting enzyme inhibitors (ACEi)  
  - Angiotensin receptor blockers (ARB)  
  - Mineralocorticoid receptor antagonists (MRA)  
  - Angiotensin receptor‑neprilysin inhibitors (ARNi)  
- β‑blockers  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
  - Empagliflozin (EMPEROR‑Preserved trial)  
- Empa‑Cardio (context of SGLT2i trials)  
- SPRINT (Systolic Blood Pressure Intervention) trial  
- AHA/ACC/HFSA Heart Failure Guideline (2022)  
- Heart failure mortality  
- Heart failure hospitalizations  
- Quality of life (QOL)  
- Estimated glomerular filtration rate (eGFR)  
- Chronic heart failure  
- Cardiovascular events  
- Rhythm and rate control in AF  
- Clinical practice guideline for hypertension  
- Comprehensive AF care in HFpEF  
- Coronary artery disease management in HFpEF  
- Exercise intolerance (chronotropic incompetence)  

These are the principal terms related to heart disease that appear in the provided guideline excerpt.

Page 57 Extracted Terms:
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Atrial fibrillation (AF)  
- β‑blockers (e.g., bisoprolol)  
- Digoxin  
- Mineralocorticoid receptor antagonists (MRAs) – spironolactone  
- N‑terminal pro–brain natriuretic peptide (NT‑proBNP)  
- Hyperkalemia  
- Renal function / creatinine  
- Estimated glomerular filtration rate (eGFR)  
- Potassium levels  
- Renin–angiotensin–aldosterone system (RAAS) inhibition  
- Angiotensin receptor blockers (ARBs) – candesartan, valsartan  
- Angiotensin receptor neprilysin inhibitor (ARNi) – sacubitril‑valsartan  
- TOPCAT trial  
- CHARM‑Preserved trial  
- PARAMOUNT‑HF trial  
- PARAGON‑HF trial  
- Left‑ventricular ejection fraction (LVEF)  
- Diastolic function  
- Pulmonary congestion  
- Exercise tolerance  
- Nitrate therapy  
- Cardiovascular death  
- Heart‑failure hospitalization  
- Composite endpoints (e.g., cardiovascular death or HF hospitalization)

Page 58 Extracted Terms:
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Nitrates (e.g., isosorbide mononitrate)  
- Phosphodiesterase‑5 inhibition (e.g., sildenafil)  
- NT‑proBNP  
- Cardiac amyloidosis  
- Transthyretin amyloidosis (ATTR)  
- ATTR wt (wild‑type ATTR)  
- ATTR v (variant ATTR)  
- Light‑chain amyloidosis (AL‑CM)  
- Serum monoclonal light chains  
- Serum free light chains (FLC)  
- Immunofixation electrophoresis (IFE)  
- Bone scintigraphy  
- 99mTc‑PYP scan (technetium‑99m pyrophosphate)  
- LV wall thickness ≥ 14 mm  
- Electrocardiogram QRS voltage  
- Apical sparing of LV longitudinal strain  
- LV longitudinal strain  
- Late gadolinium enhancement on cardiac MRI  
- Cardiac MRI  
- Aortic stenosis  
- Carpal tunnel syndrome  
- Lumbar spinal stenosis  
- Autonomic neuropathy  
- Sensory polyneuropathy  
- Peak VO₂  
- Exercise tolerance  
- Oxygen consumption  
- Dyspnea  
- Fatigue  
- Chest pain  
- Quality of life (QOL)  
- NEAT‑HFpEF trial  
- RELAX trial  

Page 59 Extracted Terms:
**Key heart‑disease related terms extracted**

- ATTR-CM (transthyretin amyloid cardiomyopathy)  
- ATTRv (variant transthyretin amyloidosis)  
- ATTRwt (wild‑type transthyretin amyloidosis)  
- Amyloid cardiomyopathy (AL‑CM)  
- Atrial fibrillation (AF)  
- Congestive heart failure (CHF)  
- Hypertension  
- Diabetes mellitus  
- Stroke  
- Transient ischemic attack (TIA)  
- Vascular disease  
- Sex category (as part of CHA2DS2‑VASc score)  
- ECG (electrocardiogram)  
- H/CL (heart to contralateral chest ratio)  
- HFrEF (heart failure with reduced ejection fraction)  
- IFE (immunofixation electrophoresis)  
- MRI (magnetic resonance imaging)  
- NYHA (New York Heart Association) classification  
- PYP (pyrophosphate) scintigraphy  
- Tc (technetium) labeling  
- TTR (transthyretin protein)  
- Genetic sequencing of the TTR gene  
- Genetic counseling  
- Family screening  
- Inotersen (drug for ATTRv)  
- Patisiran (drug for ATTRv)  
- AHA/ACC/HFSA Heart Failure Guideline 2022  

These terms capture the central clinical concepts, diagnostic methods, therapeutic agents, and guideline frameworks discussed in the text.

Page 60 Extracted Terms:
- Cardiac amyloidosis  
- ATTR‑CM (transthyretin cardiac amyloidosis)  
- Wild‑type transthyretin (ATTRwt)  
- Variant transthyretin (ATTRv)  
- Transthyretin tetramer stabilizer  
- Tafamidis  
- New‑tarry “high‑value” cardiac therapeutic economics (QALY)  
- Heart failure (HF)  
- New York Heart Association (NYHA) class I–III symptoms  
- G‑protein‑coupled receptor blockers (ARNi)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin‑receptor blocker (ARB)  
- β‑blocker  
- Implantable cardio‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Autonomic dysfunction in amyloidosis  
- Disease‑modifying therapies for ATTR – TTR silencers (inotersen, patisiran)  
- Disease‑modifying therapies – TTR stabilizers (diflunisal, tafamidis)  
- Disease‑modifying therapies – TTR disruptors (doxycycline, tauroursodeoxycholic acid [TUDCA], epigallocatechin‑3‑galate [EGCG])  
- Light‑chain (AL) amyloidosis  
- Cardiac involvement in AL amyloidosis  
- Intracardiac thrombosis  
- Atrial fibrillation (AF)  
- Anticoagulation (direct oral anticoagulants [DOACs])  
- CHA₂DS₂‑VASc score  
- Left ventricular (LV) mass  
- End‑stage renal function (eGFR < 25 mL/min/1.73 m²)  
- Cardiovascular morbidity and mortality  
- Cardiovascular‑related hospitalization  
- Economic value of cardiovascular therapies (cost per QALY)

Page 61 Extracted Terms:
- Heart Failure (HF)  
- Advanced Heart Failure (Stage D)  
- LVAD (left ventricular assist device)  
- Cardiac transplantation  
- Palliative care  
- Inotropes (intravenous)  
- NYHA (New York Heart Association) class  
- Natriuretic peptides (BNP/NT‑proBNP)  
- End‑organ dysfunction  
- Ejection fraction (EF / LVEF)  
- Low EF threshold (≤35 %, ≤30 % in ESC criteria)  
- High EF with diastolic dysfunction (≥40 %)  
- Hospitalization for HF  
- Edema despite diuretics  
- Low systolic blood pressure (≤90 mm Hg)  
- Elevated heart rate  
- Prognostic medications (GDMT)  
- GDMT (guideline‑directed medical therapy)  
- INTERMACS profiles  
- ESC (European Society of Cardiology)  
- ATTR‑CM (transthyretin amyloid cardiomyopathy)  
- Atrial fibrillation (AF)  
- Warfarin  
- Left atrial appendage closure devices  
- Bleeding risk in HF patients  
- AL amyloidosis  
- Hemostatic abnormalities (coagulation factor deficiencies, hyperfibrinolysis, platelet dysfunction)  
- TTR amyloidosis (transthyretin)  
- Cardiogenic shock  
- Malignant arrhythmias  
- 6‑minute walk test distance  
- Peak VO₂ (cardiac exercise capacity)

Page 62 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Heart failure (HF)  
- Advanced heart failure (Adv. HF)  
- Hyponatremia  
- Fluid restriction  
- Congestive symptoms  
- Diuretic‑refractory congestion  
- New York Heart Association (NYHA) functional classification  
- HFrEF – Heart Failure with reduced ejection fraction  
- HFpEF – Heart Failure with preserved ejection fraction  
- Quality of life (QOL)  
- INTERMACS profiles (cardiogenic shock, inotropic dependence, etc.)  
- Cardiogenic shock  
- Inotropic/pressor support  
- Orthopnea  
- Shortness of breath / dyspnea  
- Ascites  
- Lower extremity edema  
- Implantable cardioverter‑defibrillator (ICD)  
- Intravenous diuretics  
- Ultrafiltration  
- Mechanical circulatory support (e.g., temporary circulatory support devices)  
- Arrhythmia (ventricular tachyarrhythmia, ICD shock)  
- Clinical outcomes  
- Patient‑reported outcomes  
- Nutritional counseling (cachexia, malnutrition)  
- Sodium restriction  
- Decompensated heart failure  
- Hospitalization & mortality rates (related to HF management)

Page 63 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Heart Failure (HF)  
- Advanced (Stage D) HF  
- Guideline‑Directed Medical Therapy (GDMT)  
- Mechanical Circulatory Support (MCS)  
- Cardiac transplantation  
- Inotropic support / inotropes  
- Continuous intravenous inotropic therapy  
- Palliative inotropic therapy  
- Phosphodiesterase inhibition  
- Adrenergic receptor stimulation  
- Dopaminergic receptor stimulation  
- Calcium sensitization  
- End‑organ hypoperfusion  
- Systolic dysfunction  
- Low blood pressure (SBP ≤ 90 mm Hg)  
- Low cardiac index  
- New York Heart Association (NYHA) functional class III–IV  
- Peak VO₂ (< 14 mL/kg/min or < 50 % predicted)  
- 6‑minute walk test distance (< 300 m or inability to walk 1 block)  
- Renin–Angiotensin–Aldosterone System inhibitors (RAASi)  
- Beta‑blockers  
- Diuretics (furosemide, metolazone)  
- Diuretic escalation (> 160 mg/day furosemide equivalent)  
- Ventricular arrhythmias / ICD shocks  
- Cardiac cachexia  
- Hyponatremia (serum sodium < 134 mEq/L)  
- Declining renal function  
- Declining hepatic function  
- Pulmonary hypertension / right HF  
- Predicted 1‑year mortality (> 20 %)  
- MAGGIC (Meta‑analysis Global Group in Chronic Heart Failure)  
- SHFM (Seattle Heart Failure Model)  
- Cardiac Resynchronization Therapy (CRT)  
- Inotrope dependence  
- Low peak VO₂ (< 14–16 mL/kg/min)  
- End‑organ dysfunction due to low cardiac output  
- Irreversible hepatic disease  
- Irreversible renal disease  
- Irreversible neurological disease  
- Age > 80 years (destination therapy)  
- Peripheral vascular disease (PVD)  
- Neurohormonal antagonists  
- Social / psychosocial limitations  
- Medication non‑adherence  
- Active systemic infection  
- Malnutrition / obesity  
- Musculoskeletal limitations  
- Active malignancy  
- Substance abuse  
- Cognitive / psychiatric impairment  
- Lack of social support  
- Implantable cardioverter‑defibrillator (ICD)  

These terms capture the key concepts and clinical markers related to heart disease discussed in the guideline excerpt.

Page 64 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Advanced HFrEF  
- NYHA Class IV  
- Inotropes  
- Bridge Therapy  
- Heart Transplantation  
- Mechanical Circulatory Support (MCS)  
- Durable LVAD  
- Durable MCS  
- Temporary MCS  
- Percutaneous Ventricular Assist Devices (VAD)  
- Extracorporeal Ventricular Assist Devices  
- Bridge to Recovery  
- Bridge to Decision  
- Palliation  
- Arrhythmias  
- Inappropriate Shocks  
- ICD (Implantable Cardioverter‑Defibrillator)  
- Beta Blockers  
- Myocardial Oxygen Demand  
- Pulmonary Hypertension  
- End‑Organ Perfusion  
- Mortality  
- Survival  
- Quality of Life (QOL)  
- Functional Status  
- GDMT (Guideline‑Directed Medical Therapy)  
- Hemodynamic Compromise  
- Shock  
- Intravenous Inotropic Agents  
- Dopamine  
- Dobutamine  
- Milrinone  
- Epinephrine  
- Norepinephrine  
- Adrenergic Agonists  
- Phosphodiesterase 3 Inhibitors (PDE3)  
- Vasopressors  
- Monoamine Oxidase Inhibitor (MAO‑I)

Page 65 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Pump mechanisms (mechanically assisted circulatory support)  
- Ventricular assist devices (VADs) – specifically Left Ventricular Assist Devices (LVADs)  
- Mechanical circulatory support (MCS)  
- Durable MCS / Destination therapy  
- Temporary MCS / Bridge therapy  
- Inotropic therapy (intravenous inotropes)  
- N-terminal pro–B-type natriuretic peptide (NT‑proBNP) – (implicit in HF assessment)  
- New York Heart Association (NYHA) class IV  
- INTERMACS profiles (1–7, Interagency Registry for Mechanically Assisted Circulatory Support)  
- Pulmonary hypertension  
- Central venous pressure  
- Coagulopathy / anticoagulation management  
- Pump thrombosis  
- Hemolysis  
- Ischemic neurologic events  
- Anticoagulation monitoring (INR levels)  
- Glycemic‑diabetes‑management therapy (GDMT) – (implicit in HF treatment)  
- Cardiogenic shock  
- Cardiac transplantation  
- Bridge‑to‑transplant (BTT)  
- Destination therapy (DT)  
- Quality‑adjusted life‑year (QALY)  
- Cost‑effectiveness / incremental cost‑effectiveness ratio (ICER)  
- Hospital readmission / re‑hospitalization  
- Percutaneous lead & external power supplies (device complications)  
- Multidisciplinary heart‑failure team (cardiologist, surgeon, nurse, pharmacist, dietitian, palliative specialist, social worker)

Page 66 Extracted Terms:
**Key Terms Related to Heart Disease**

- Advanced heart failure (HF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Cardiac transplantation  
- Left Ventricular Assist Device (LVAD)  
- Mechanical Circulatory Support (MCS)  
- Stage D heart failure  
- Survival benefit  
- Quality of life (QOL)  
- Donor allocation policy  
- Waitlist mortality  
- Temporary circulatory support devices  
- Multiorgan transplantation  
- Congestion assessment  
- Perfusion adequacy  
- Cardiopulmonary exercise testing (CPET)  
- Pulmonary hypertension  
- Congenital heart disease  
- Hypertrophic cardiomyopathy  
- Muscular dystrophy (cardiac involvement)  
- Sarcoidosis (cardiac involvement)  
- Amyloidosis (cardiac involvement)  
- Inotrope‑dependent advanced HF  
- Cost‑effectiveness analysis  
- Bridge‑to‑transplant strategy  
- Bridge‑to‑decision strategy  
- Destination therapy strategy  
- Reversible factor management  
- Volume status optimization  
- Functional status improvement  
- Health‑related quality of life  
- Refractory heart failure  
- Post‑transplant outcomes  

These terms encompass the principal clinical conditions, therapeutic modalities, assessment tools, and outcome measures discussed in the guideline excerpts.

Page 67 Extracted Terms:
- Cardiogenic shock  
- Heart failure (HF)  
- Acute coronary syndrome (ACS)  
- Revascularization  
- Ischemia  
- Arrhythmia / ventricular arrhythmia  
- Tricuspid regurgitation (TR)  
- Preserved left ventricular ejection fraction (LVEF)  
- Reduced EF / HFrEF  
- HFpEF (heart failure with preserved ejection fraction)  
- Pulmonary edema  
- Hypertension / uncontrolled hypertension  
- Right‑sided filling pressures  
- Left‑sided filling pressures  
- Natriuretic peptides (e.g., BNP, NT‑proBNP)  
- Congestion / decongestion  
- Hypoperfusion (resting, low pulse pressure)  
- Neurohormonal antagonists (e.g., ACEi, ARBs, beta‑blockers, MRAs)  
- Diuretic therapy  
- Guideline‑directed medical therapy (GDMT)  
- Cardiac resynchronization therapy (CRT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Anticoagulation for atrial fibrillation (AF)  
- Anemia  
- Hyper‑ or hypothyroidism  
- Non‑steroidal anti‑inflammatory drug (NSAID) use  
- Medications with negative inotropic effect (e.g., verapamil)  
- Pulmonary or urinary tract infections (as precipitants of HF)  
- Social determinants of health (impact on HF management)

Page 68 Extracted Terms:
- Heart failure with reduced ejection fraction (HFrEF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin receptor blocker (ARB)  
- Angiotensin receptor‑neprilysin inhibitor (ARNi)  
- Beta‑blocker (β‑blocker)  
- Mineralocorticoid receptor antagonist (MRA)  
- Diuretic therapy  
- Hospitalization for heart failure  
- Post‑discharge mortality  
- Hospital readmission  
- Renal function (e.g., serum creatinine, eGFR)  
- Systolic blood pressure (SBP)  
- Estimated glomerular filtration rate (eGFR)  
- Acute kidney injury (AKI)  
- Cardiac output  
- Cardiogenic shock  
- Atrioventricular (AV) block  
- Angioedema  
- Oral GDMT  
- Target GDMT dose  
- Clinical stability  
- Optimal dosing  
- Mortality risk  
- Rehospitalization risk  
- OPTIMIZE‑HF study  
- CHAMP‑HF registry  
- PARADIGM‑HF trial  
- SENIORS trial  
- Val‑HeFT trial  
- Carvedilol  
- Nebivolol  
- Spironolactone  
- Sacubitril‑valsartan  
- AHA/ACC/HFSA Heart Failure Guideline  
- Get With The Guidelines–Heart Failure (GWTG‑HF) registry  
- COACH study  
- ARIC study (Atherosclerosis Risk in Communities)  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- In‑hospital mortality  
- Short‑term mortality  
- Long‑term mortality  
- Volume overload  
- Suboptimal dose of GDMT


Page 69 Extracted Terms:
- AHA/ACC/HFSA Heart Failure Guideline  
- Carvedilol  
- Beta blockers  
- ACEi‑ARB (angiotensin‑converting‑enzyme inhibitor / angiotensin‑II receptor blocker)  
- MRA therapy (mineralocorticoid‑receptor antagonist)  
- Spironolactone  
- ARNi (angiotensin receptor‑neprilysin inhibitor)  
- NT‑proBNP (N‑terminal pro‑B‑type natriuretic peptide)  
- Worsening renal function  
- Hyperkalemia  
- Symptomatic hypotension  
- Angioedema  
- Oral GDMT (guideline‑directed medical therapy)  
- HFrEF (heart failure with reduced ejection fraction)  
- HF readmission / rehospitalization  
- Decongestion strategy  
- Loop diuretics (intravenous)  
- Thiazide diuretic (add‑on)  
- Furosemide (oral loop diuretic)  
- GWTG‑HF (Get With The Guidelines‑Heart Failure)  
- COACH trial  
- PIONEER‑HF trial  
- ARIC study  
- SOLOIST‑WHF trial  
- CHAMP‑HF study  
- 30‑day mortality  
- 1‑year mortality  
- Target doses of beta blockers, ACEi‑ARB, ARNi, MRA  
- Monotherapy, dual therapy, triple therapy (GDMT combinations)  
- Clinical evidence of congestion  
- Symptoms and rehospitalizations (mortality)

Page 70 Extracted Terms:
- Heart failure (HF)
- Heart failure with reduced ejection fraction (HFrEF)
- Congestion
- Decompensated heart failure
- Acute heart failure
- Pulmonary congestion
- Dyspnea
- Right atrial pressure
- Tricuspid regurgitation (TR)
- Elevated filling pressures
- Hypoperfusion
- Renal dysfunction
- Serum electrolytes
- Urea nitrogen
- Creatinine
- Fluid input/output monitoring
- Standing body weight
- Intravenous loop diuretics
- Diuretic dose escalation
- Serial doubling of loop diuretics
- Nephron blockade
- Thiazide diuretic
- Ultrafiltration
- Intravenous nitroglycerin
- Intravenous nitroprusside
- ACE inhibitors (ACEi)
- Angiotensin receptor blockers (ARBs)
- Mineralocorticoid receptor antagonists (MRAs)
- Beta‑blockers
- ARNI (angiotensin receptor‑neprilysin inhibitor)
- SGLT2 inhibitors (SGLT2i)
- Inotropic support
- Cardiogenic shock
- Left ventricular ejection fraction (LVEF)
- Low‑dose dopamine therapy
- Ejection fraction (EF)
- Diuretic optimization
- Hospital readmission
- Mortality
- Clinical signs of congestion
- Hospital discharge criteria
- Continuous infusion vs. bolus diuretic administration
- Fluid removal rate
- Vascular access complications
- Hypotension (systemic and pulmonary)
- Hypotensive management in HF
- Renal impairment monitoring
- Fluid overload
- Diuretic therapy monitoring
- Guideline‑directed medical therapy for HF
- CARRESS trial
- ROSE trial
- DOSE trial
- Parenteral vasodilator therapy
- Inotropic support trials
- Cardiogenic shock management
- Fluid balance management in HF
- Electrolyte monitoring in diuretic therapy

Page 71 Extracted Terms:
- Heart failure (HF)
- Acute decompensated heart failure
- Pulmonary congestion
- Loop diuretics
- Hypertension
- Coronary ischemia
- Mitral regurgitation (MR)
- Intravenous nitroglycerin
- Tachyphylaxis
- Sodium nitroprusside
- Hypotension
- Invasive hemodynamic monitoring
- Arterial line
- Intensive care setting
- Thiocyanate toxicity
- Cyanide toxicity
- Renal insufficiency
- Hepatic disease
- Severe mitral valve (MV) regurgitation
- Left ventricular (LV) dysfunction
- Venous thromboembolism (VTE)
- VTE prophylaxis
- Low‑molecular‑weight heparin
- Unfractionated heparin
- Fondaparinux
- Direct oral anticoagulants (DOACs)
- Enoxaparin
- Rivaroxaban
- Aspirin
- Bleeding complications
- Renal function (creatinine clearance)
- Obesity (dose adjustment)
- Cardiogenic shock
- Intravenous inotropic support
- Systemic perfusion
- End‑organ performance
- Mechanical circulatory support (MCS)
- Multidisciplinary shock team
- Pulmonary artery (PA) line
- Pulmonary artery pressure
- Pulmonary embolism
- Deep vein thrombosis (DVT)
- Antithrombotic drugs
- Acute illnesses
- Severe respiratory diseases  

Page 72 Extracted Terms:
- Cardiogenic shock  
- Cardiac output  
- End‑organ dysfunction  
- Hypotension  
- Systolic blood pressure (SBP)  
- Mean arterial pressure (MAP)  
- End‑organ hypoperfusion  
- Acute decompensation of chronic heart failure (HF)  
- Acute myocardial dysfunction without prior HF  
- Survivors of cardiac arrest  
- Acute myocardial infarction (MI)  
- Revascularization  
- Invasive hemodynamic assessment  
- Mechanical circulatory support (MCS)  
- Pharmacologic therapies  
- Cardiac index  
- Pulmonary capillary wedge pressure (PCW)  
- Pulmonary artery pulse index (PAPi)  
- Central venous pressure (CVP)  
- Cardiac power output (CPO)  
- Shock index (HR/SBP)  
- Right‑ventricular (RV) shock  
- Pulmonary artery systolic pressure (PASP)  
- Pulmonary artery diastolic pressure (PADP)  
- Brain natriuretic peptide (BNP)  
- Lactate (elevated lactate)  
- Urine output (reduced urine output)  
- Mentation (altered mentation)  
- Cold extremities / livedo reticularis  
- Metabolic complications (acidosis, liver function tests)  
- SCAI cardiogenic shock stages (A–E)  
- Hemodynamic criteria for shock (SBP <90 mm Hg, MAP <60 mm Hg, CI <2.2 L/min/m², PCW >15 mm Hg, CPO <0.6 W)  
- Shock index >1.0  
- Pulmonary artery pulsatility index (PAPi) <1.0  
- Right‑ventricular measures (CVP >15 mm Hg, CVP‑PCW >0.6)  
- Cardiogenic shock diagnostic criteria  
- Acute coronary syndrome (ACS)  
- Cardiac arrest 
- Cardiac resuscitation (CPR) 
- Pulseless electrical activity (PEA) 
- Ventricular tachycardia (VT) 
- Ventricular fibrillation (VF)

Page 73 Extracted Terms:
- Cardiogenic shock  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Inotropic support  
- Mechanical circulatory support (MCS)  
- Invasive hemodynamic monitoring  
- Pulmonary artery catheterization (PA catheter)  
- End‑organ perfusion / end‑organ dysfunction  
- Left ventricular assist device (LVAD)  
- Heart transplant  
- Revascularization (e.g., percutaneous coronary intervention)  
- ST‑elevation myocardial infarction (STEMI)  
- Myocarditis  
- Arrhythmias  
- Vasopressors  
- Shock team  
- Multidisciplinary care teams (HF, critical care, interventional cardiology, cardiac surgery)  
- Palliative care  
- Transitional care / discharge planning  
- Hospitalization / readmission  
- Evidence‑based therapy  
- Clinical guidelines (AHA/ACC/HFSA)  
- Hemodynamic benefits / data  
- Cardiac output  
- Blood pressure  
- Organ hypoperfusion  
- Pharmacologic therapy  
- Mechanical therapy  
- Temporary circulatory support devices  
- Bridge‑to‑decision strategies  
- Durable LVAD or transplant pathways  
- End‑organ malperfusion  
- Risk assessment and therapeutic decision‑making  
- Early follow‑up (within 7 days of discharge)  
- Benchmarking to performance measures  
- Quality of care metrics  
- Cardiovascular disease management programs  
- Clinical statements and recommendations  
- Hemodynamics (hemodynamic monitoring, monitoring of pulmonary pressures, systemic vascular resistance)

Page 74 Extracted Terms:
**Heart‑disease–related terms extracted from the text**

1. Heart failure (HF)  
2. HFrEF (heart‑failure with reduced ejection fraction)  
3. HFpEF (heart‑failure with preserved ejection fraction)  
4. Guideline‑directed medical therapy (GDMT)  
5. Decompensation (HF decompensation)  
6. Readmission / rehospitalization  
7. Multidisciplinary care / team  
8. Case management (case manager, nurse coordinator)  
9. Cardiologists  
10. HF nurses  
11. Primary‑care clinicians  
12. Pharmacists  
13. Dietitians  
14. Social workers  
15. Community health workers  
16. Disease‑management programs  
17. Self‑management  
18. Medication optimization / reconciliation  
19. Device management (pacemakers, defibrillators, etc.)  
20. Weight monitoring  
21. Exercise counseling / rehabilitation  
22. Dietary advice / restrictions  
23. Cardiac rehabilitation  
24. Discharge medications  
25. Follow‑up appointments  
26. Transition of care  
27. Performance‑measure benchmarks (real‑time feedback)  
28. Quality‑improvement programs  
29. Electronic point‑of‑care reminders (for GDMT)  
30. Outpatient follow‑up  
31. Early post‑discharge follow‑up  
32. Diuretics (titration, adjustment)  
33. Electrolytes monitoring  
34. Safety laboratory checks  
35. Renal dysfunction (comorbidity)  
36. Pulmonary disease (comorbidity)  
37. Diabetes (comorbidity)  
38. Mental health (comorbidity)  
39. Substance‑use disorders (comorbidity)  
40. Psychosocial support (limitations)  
41. Health literacy (impaired)  
42. Cognitive impairment  
43. Additional surgical or device therapy  
44. Palliative‑care referral  
45. Hospice enrollment

These are the key terms that relate to heart disease management and care outlined in the provided guideline excerpts.

Page 75 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Neuro‑hormonal guideline‑directed medical therapy (GDMT)  
- Intravenous iron replacement for iron deficiency in HF  
- Erythropoietin‑stimulating agents (contraindicated in HF)  
- Hypertension  
- Ischemic heart disease (IHD)  
- Diabetes mellitus type 2  
- Anemia  
- Chronic kidney disease (CKD)  
- Chronic obstructive pulmonary disease (COPD)  
- Atrial fibrillation (AF)  
- Sleep‑disordered breathing  
- Obstructive sleep apnea (OSA)  
- Central sleep apnea (CSA)  
- Continuous positive airway pressure (CPAP)  
- Adaptive servo‑ventilation (avoided in CSA)  
- Sodium‑glucose co‑transporter‑2 inhibitors (SGLT2i)  
- Telemedicine/virtual visits for chronic HF management  
- Functional status improvement  
- Quality of life (QoL) enhancement  
- Multimorbidity in HF (≥2 chronic conditions)  
- Morbid obesity  
- Frailty  
- Malnutrition  
- Depression (impacting HF prognosis)

Page 76 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin Receptor Blockers (ARB)  
- Sodium‑Glucose Cotransporter‑2 Inhibitors (SGLT2i)  
- Cardiac Resynchronization Therapy (CRT)  
- Valvular Heart Disease (VHD)  
- Atrial Fibrillation (AF)  
- New York Heart Association (NYHA) Classification  
- Left Ventricular Ejection Fraction (LVEF)  
- CHA₂DS₂‑VASc Score (stroke‑risk assessment in AF)  
- Continuous Positive Airway Pressure (CPAP) – for sleep apnea related to HF  
- Ferric Carboxymaltose – iron therapy used in HF with iron deficiency  
- Anemia – frequently present and prognostic in HF  
- Chronic Kidney Disease (CKD) – closely linked comorbidity impacting HF management  

(These terms capture the core heart‑disease concepts, associated therapies, diagnostic metrics, and key comorbidities discussed in the guideline text.)

Page 77 Extracted Terms:
**Key Terms Related to Heart Disease**

- Heart Failure (HF)  
- Chronic Heart Failure  
- Heart Failure with reduced Ejection Fraction (HFrEF)  
- Left Ventricular Ejection Fraction (EF)  
- EF < 50 %  
- EF ≤ 40 %  
- New York Heart Association (NYHA) Class II, III, IV  
- 6‑minute walk test  
- Quality of Life (QOL)  
- Iron Deficiency Anemia  
- Oral iron supplementation  
- Intravenous iron therapy  
- Ferric carboxymaltose  
- IRONOUT HF trial  
- AFFIRM‑AHF trial  
- Cardiovascular death  
- Hospitalization for heart failure  
- Anemia in heart failure  
- Erythropoietin  
- Erythropoietin‑stimulating agents (ESA)  
- Darbepoetin α  
- Thrombotic events (stroke, etc.)  
- Hypertension  
- Systolic blood pressure (SBP) < 120 mm Hg  
- Low blood pressure in HFrEF  
- Antihypertensive therapy  
- Guideline‑directed medical therapy (GDMT)  
- ACC/AHA hypertension guidelines  
- Sleep disorders in heart failure  
- Daytime sleepiness  
- Obstructive sleep apnea (OSA)  
- Central sleep apnea (CSA)  
- Sleep study (polysomnography)  
- Continuous positive airway pressure (CPAP)  
- Nocturnal oxygenation  
- B-type natriuretic peptide (BNP)  
- Adaptive servo‑ventilation  
- Mortality (all‑cause, cardiovascular)  
- Diabetes mellitus  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Canagliflozin  
- Dapagliflozin  
- Empagliflozin  
- Sotagliflozin  
- Major adverse cardiovascular events (MACE)  
- DAPA‑HF trial  
- EMPEROR‑Reduced trial  
- All‑cause death  
- Clinical guidelines (AHA/ACC/HFSA Heart Failure Guideline, ACC/AHA hypertension guideline)  
- Clinical trials  
- Meta‑analysis  

These terms capture the principal concepts, conditions, interventions, and outcomes discussed in the text regarding heart disease.

Page 78 Extracted Terms:
- Heart failure  
- HF  
- Chronic heart failure  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular ejection fraction (LVEF)  
- Atrial fibrillation (AF)  
- Permanent AF  
- Persistent AF  
- Paroxysmal AF  
- AF ablation  
- Antiarrhythmic therapy  
- Amiodarone  
- Atrioventricular nodal ablation  
- Cardiac resynchronization therapy (CRT) device  
- Permanent pacemaker  
- CHA₂DS₂‑VASc score  
- Anticoagulant therapy  
- Direct oral anticoagulants (DOAC)  
- Warfarin  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Dabigatran  
- SGLT2 inhibitors (SGLT2i)  
- Dapagliflozin  
- Empagliflozin  
- Hospitalization for heart failure  
- Mortality  
- Stroke prevention  
- Intracranial bleeding  
- Major bleeding  
- Genitourinary infections (risk factor)  
- Renal outcomes  
- NYHA functional class  
- Ventricular rate control  
- Rhythm control strategy  
- Catheter ablation (AF)  
- Cardiology guideline terminology  



Page 79 Extracted Terms:
- Heart Failure (HF)  
- Atrial Fibrillation (AF)  
- Rhythm control strategy  
- Rate control strategy  
- Catheter ablation  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Cardiac Resynchronization Therapy (CRT)  
- Right‑Ventricular (RV) pacing  
- Left‑Ventricular–Based Cardiac Stimulation (PAVE)  
- Biventricular versus Right‑Ventricular Pacing (BLOCK‑HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- New York Heart Association (NYHA) class II‑IV  
- Composite endpoint: death or rehospitalization  
- Hazard ratios and relative risk reductions (e.g., 49%, 56%)  
- CHA₂DS₂‑VASc score  
- Hypercoagulable state in HF  
- Stroke risk  
- Systemic embolism  
- Anticoagulation therapy  
- Clinical trial meta‑analysis of rhythm vs. rate control  
- Clinical statements and guidelines (AHA/ACC/HFSA 2022 HF Guideline)  
- Health disparities / vulnerable populations  
- Social determinants of health  
- Hypertension prevalence in Black patients  
- Polypharmacy, multimorbidity, cognitive decline, frailty  
- Women’s heart failure presentation and outcomes  
- Black patient HF incidence, hospitalization, mortality rates  
- Implicit bias training in healthcare  
- Implicit bias in clinical decision‑making  
- Genotype or race‑based cardiovascular risk  
- Clinical practice monitoring of health disparities  
- Multidisciplinary management strategies for HF  
- GDMT (guideline‑directed medical therapy)  
- Stroke registry data in HF with AF  
- HF as an independent risk factor for stroke, systemic embolism, mortality  

(Note: terms are grouped thematically but all are listed individually.)

Page 80 Extracted Terms:
**Key heart‑disease–related terms extracted from the text**

- Heart Failure (HF)  
- Heart Failure with preserved ejection fraction (HFpEF)  
- Heart Failure with reduced ejection fraction (HFrEF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular Assist Device (LVAD)  
- Chagas cardiomyopathy  
- Cardiovascular disease (CVD)  
- Transplant wait‑list mortality  
- Age‑adjusted HF mortality  
- Incident HF risk  
- Non‑ischemic HF  
- Ischemic HF  
- Social isolation  
- Caregiver support / caregiver stress  
- Low household income / low socioeconomic status  
- Neighborhood Deprivation Index (ADI)  
- Diabetes mellitus  
- Hypertension  
- Obesity  
- Anxiety  
- Depression  
- Female sex / women (sex‑specific differences)  
- Older adults (≥ 80 years, ≥ 65 years)  
- Low‑income populations  
- Black/African‑American populations  
- Hispanic/Latino populations  
- Asian and Pacific Islander populations  
- Native American and Alaskan Native populations  
- Framingham Heart Study (FHS)  
- Multi‑Ethnic Study of Atherosclerosis (MESA)  
- Get With The Guidelines (GWTG) registry  
- OPTMIZE‑HF registry (Organized Program To Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)  
- AHA/ACC/HFSA Heart Failure Guideline  
- Hospitalization rates for HF  
- Quality of Life (QOL) measures  
- Mortality (short‑term, 1‑year, 5‑year, overall)  
- Hazard Ratio (HR)  
- Odds Ratio (OR)  
- Predictive value of cardiac biomarkers for incident HF  

These terms encompass the clinical conditions, therapies, risk factors, outcomes, population groups, and research/registry references that are central to heart disease discussion in the provided text.

Page 81 Extracted Terms:
**Key heart‑disease related terms**

- Heart failure (HF)  
- HF incidence  
- HF mortality  
- Heart transplantation  
- Cardiovascular risk factors  
- Cardiovascular complications of cancer therapy  
- Cardiotoxic anticancer therapies  
- Cardio‑oncology (practice of cardiovascular risk stratification in oncology)  
- Cardiomyopathy (including cancer‑therapy–related cardiomyopathy)  
- Left ventricular ejection fraction (LVEF)  
- LV dysfunction  
- Asymptomatic cardiomyopathy (EF < 50 %)  
- Cardiac troponin  
- Progressive heart failure  
- Advanced heart failure therapies  
- Beta‑blockers (β‑blockers)  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin‑II receptor blockers (ARB)  
- Cardiac function monitoring  
- Cardiac function baseline assessment  
- Cardiogenic shock  
- Primary prevention of drug‑induced cardiomyopathy  
- Early detection of cardiomyopathy  
- Multidisciplinary heart‑failure management  
- CVD (cardiovascular disease)  
- Integrated cardio‑oncology framework  
- Cardio‑vascular risk stratification  
- High‑quality, drug‑specific evidence for cardiotoxicity screening and monitoring  

These terms capture the core concepts and therapies related to heart disease discussed in the provided text.

Page 82 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Cardiotoxicity  
- Cancer‑therapy‑related cardiomyopathy  
- Cardiac dysfunction  
- Left ventricular ejection fraction (LVEF)  
- Neurohormonal blockade  
- Guideline‑directed medical therapy (GDMT)  
- Beta‑blockers  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin‑II receptor blockers (ARBs)  
- Immune‑checkpoint–related myocarditis  
- Anthracyclines  
- Alkylating agents  
- Antimicrotubule agents  
- Antimetabolites  
- Anti‑HER2 agents  
- Tyrosine‑kinase inhibitors  
- Immune‑checkpoint inhibitors  
- Protease inhibitors  
- Endocrine therapy  
- Chimeric antigen receptor (CAR‑T) cell therapy  
- Hematopoietic stem cell transplantation (HSCT)  
- Chest radiation therapy  
- Echocardiography  
- Cardiac monitoring  
- Cardiac imaging  
- Pre‑therapy LVEF assessment  
- Cardiac risk stratification  
- Cardiovascular disease (CVD)  
- Major adverse cardiovascular events (MACE)  
- Cardiac safety assessment  
- Standard heart‑failure therapies (e.g., diuretics, mineralocorticoid antagonists)  


These terms encompass the core concepts and modalities related to heart disease discussions within the provided clinical guideline excerpt.

Page 83 Extracted Terms:
**Key heart‑disease terms extracted**

- Heart failure  
- Cardiomyopathy  
- Cancer therapy‑related cardiomyopathy  
- Left ventricular ejection fraction (LVEF)  
- New York Heart Association (NYHA) class I–II  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin II receptor blockers (ARB)  
- β‑blockers  
- Spironolactone  
- Carvedilol  
- Nebivolol  
- Anthracyclines  
- Trastuzumab  
- Serial LVEF monitoring  
- Troponin  
- Natriuretic peptides  
- Coronary artery disease (CAD)  
- Hypertension  
- Diabetes mellitus  
- Preexisting cardiomyopathy  
- Previous anthracycline exposure  
- Previous chest radiation  
- Age ≥60 years  
- Black race  
- Elevated pre‑therapy troponin (≥14 ng/L or >0.07 ng/mL)  
- ≥10 % LVEF decline to <50 %  
- LVEF recovery  
- Cardiac events (mortality, heart‑failure hospitalization)  
- Echocardiography  
- Cardiac risk stratification  
- AHA/ACC/HFSA heart‑failure guideline  
- Cancer‑therapy cardiotoxicity  
- Biomarker‑guided therapy  
- Subclinical cardiac injury  
- Temporary/permanent interruption of cardiotoxic agents  

These terms collectively capture the heart‑disease concepts discussed in the guideline excerpt.

Page 84 Extracted Terms:
Heart failure (HF)  
Cardiomyopathy  
Peripartum cardiomyopathy  
Left ventricular ejection fraction (LVEF)  
Left ventricular (LV) dilation  
Left ventricular (LV) dysfunction  
Right ventricular (RV) involvement  
NYHA functional class  
AHA/ACC/HFSA Heart Failure Guideline  
Systolic dysfunction  
Acute HF  
Cardiogenic shock  
Intracardiac thrombus  
Thromboembolic events  
Hypercoagulable state  
Anticoagulation  
Bromocriptine  
Dopamine‑agonist therapy  
GDMT (guideline‑directed medical therapy)  
ACE inhibitor (ACEi)  
Angiotensin receptor blocker (ARB)  
Angiotensin receptor‑neprilysin inhibitor (ARNi)  
Mineralocorticoid receptor antagonist (MRA)  
SGLT2 inhibitor (SGLT2i)  
Ivabradine  
Vericiguat  
Mechanical circulatory support  
Left ventricular assist device (LVAD)  
Heart transplant  
Pregnancy in cardiomyopathy  
Risk factors: maternal age >30 yr, African ancestry, multiparity, multigestation, preeclampsia/eclampsia, anemia, diabetes, obesity, prolonged tocolysis  
ROPAC registry  
CARPREG II score  
Modified WHO risk classification  
World Health Organization (WHO) risk score for pregnancy and cardiac disease

Page 85 Extracted Terms:
- AHA/ACC/HFSA Heart Failure Guideline  
- Heart Failure (HF)  
- Peripartum Cardiomyopathy (PPCM)  
- Left Ventricular Ejection Fraction (LVEF)  
- Right Ventricular (RV)  
- Angiotensin‑converting Enzyme Inhibitor (ACEi)  
- Angiotensin Receptor Blocker (ARB)  
- Angiotensin Receptor‑Neprilysin Inhibitor (ARNi)  
- Mineralocorticoid Receptor Antagonist (MRA)  
- Sodium‑Glucose Cotransporter‑2 Inhibitor (SGLT2i)  
- Beta‑Blocker (e.g., metoprolol, metoprolol succinate)  
- Hydralazine  
- Nitrates (e.g., nitroglycerin)  
- Diuretics (e.g., furosemide)  
- Anticoagulation (prophylactic or therapeutic)  
- Bromocriptine  
- Mechanical Circulatory Support (MCS)  
- Cardiogenic Shock  
- Decompensated Heart Failure  
- Guideline‑Directed Medical Therapy (GDMT)  
- B‑natriuretic Peptide (BNP)  
- N‑terminal pro‑B‑natriuretic Peptide (NT‑proBNP)  
- Echocardiography (cardiac structure & function assessment)  
- Pregnancy Cardiovascular Risk Tools  
- Preconception Genetic Counseling & Testing for Heritable Cardiac Conditions  
- Preeclampsia (shared risk with PPCM)  
- Maternal‑Fetal Medicine Surveillance  
- Breastfeeding‑safe Medications (ACEi, beta‑blockers, diuretics)  
- ESC “BOARD” (Bromocriptine, Oral HF therapy, Anticoagulation, vaso‑Relaxing agents, Diuretics)  
- Randomized Controlled Trial (RCT) evidence on PPCM and bromocriptine  
- Clinical Statements & Guidelines (2022)  
- Perinatal (Pregnancy Continuum) HF Management Strategies  
- Multidisciplinary Collaborative Approach (cardiology, obstetrics, neonatology, genetics)

Page 86 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with reduced ejection fraction (HFrEF)  
- Heart Failure guidelines (AHA/ACC/HFSA, 2022)  
- Pregnancy and Lactation Labeling Rule  
- Angiotensin‑converting enzyme inhibitors (ACEi) – e.g., enalapril, captopril  
- Angiotensin‑II receptor blockers (ARBs)  
- Angiotensin receptor neprilysin inhibitors (ARNi)  
- Ivabradine  
- Spironolactone  
- Eplerenone  
- Loop diuretic (furosemide)  
- Beta‑blockers (metoprolol, other)  
- Hydralazine  
- Nitrates  
- Peripartum cardiomyopathy  
- Left ventricular recovery (LV recovery)  
- LactMed (Lactation Medications database)  
- Performance measurement / quality metrics in heart failure care  
- Process‑of‑care measures  
- NYHA functional class I and III  
- Patient registries for heart‑failure quality improvement  
- Palliative and supportive care in heart failure  
- Quality of life (QOL)  
- Life‑extending therapies in HF  
- Stage D heart failure  
- Inotropic support  
- Temporary mechanical support  
- Advanced therapies (e.g., transplant, mechanical circulatory support)  
- Multimorbidity, frailty, cognitive impairment in HF patients  
- Shared decision‑making (multidisciplinary)  
- Clinical practice guidelines (ACC/AHA)

Page 87 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with reduced ejection fraction (HFrEF)  
- Advanced Heart Failure (advanced HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Beta‑blocker therapy for HFrEF  
- ACE inhibitor (ACEi) therapy for HFrEF  
- Angiotensin‑receptor blocker (ARB) therapy for HFrEF  
- Angiotensin‑receptor neprilysin inhibitor (ARNi) therapy for HFrEF  
- Mineralocorticoid receptor antagonist (MRA) therapy for HFrEF  
- Hydralazine and isosorbide dinitrate therapy for HFrEF in Black or African American patients  
- Guideline‑Directed Medical Therapy (GDMT)  
- Implantable Cardioverter‑Defibrillator (ICD) placement counseling for HFrEF  
- Cardiac Resynchronization Therapy (CRT) implantation for HFrEF  
- Palliative care for patients with HF  
- Advance care planning / advance care directives in HF  
- Hospice referral for advanced HF with <6 month survival  
- Quality of Life (QOL) improvement in HF care  
- Symptom assessment and monitoring in HF  
- Symptom management in HF  
- Patient self‑care education for HF  
- Patient‑reported outcome and health status measurement in HF  
- Exercise training referral for HF (inpatient and outpatient)  
- HF registry participation  
- Performance Measures (PM) for HF  
- Quality Measures (QM) for HF  
- Structural Measures (SM) for HF

Page 88 Extracted Terms:
- Heart Failure (HF)  
- Congestive Heart Failure (CHF)  
- Mechanical Circulatory Support (MCS)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Intravenous Inotropes  
- Renal Replacement Therapy (used in advanced HF)  
- Life‑sustaining therapies (initiation, continuation, deactivation)  
- Palliative Care in HF  
- Supportive Care in HF  
- Psychological Distress (in the context of HF management)  
- Family Caregiver support (in HF care)

Page 89 Extracted Terms:
- Heart Failure (HF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Left Ventricular Assist Device (LVAD)  
- Deactivation of ICD  
- Palliative Care  
- Hospice Care  
- Advance Care Planning  
- End‑of‑Life Care  
- Symptom Management (dyspnea, fatigue, pain, nausea, depression, anxiety)  
- Shared Decision‑Making  
- High‑Quality Communication  
- Caregiver Support  
- Cardiovascular Mortality/Deaths  
- Prognostic Discussions (“hope for the best, plan for the worst”)  
- Surrogate Decision Maker  
- Life‑Sustaining Treatments (hospitalization, tube feeding, medication)  
- Palliative Care Interventions (e.g., PAL‑HF)  
- Mortality Prediction / Risk Models  
- Terminal Disease/End‑Stage HF  
- Legal and Ethical Considerations (state laws, Medicare eligibility)

Page 90 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mid‑range ejection fraction (HFmrEF)  
- Heart failure with improved ejection fraction (HFimpEF)  
- Myocarditis  
- Myocardial injury  
- COVID‑19‑associated cardiotoxicity  
- Cardiomyopathies (e.g., peripartum cardiomyopathy, ATTR cardiomyopathy)  
- Right‑ventricular (RV) failure  
- Cardiorenal syndrome  
- Diuretic resistance  
- Precise and individualized HF management  
- Biomarkers in HF therapy optimization  
- Omics and molecular markers for HF diagnosis and prognosis  
- Fluid restriction therapy  
- Sodium restriction (dietary)  
- Cardiac rehabilitation (HFpEF, HFmrEF)  
- Hydralazine‑isosorbide therapy in HF (African American and non‑African American)  
- Vericiguat for HFrEF with high natriuretic peptides  
- Omecamtiv mecarbil for advanced (stage D) HFrEF  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i) in HFpEF, HFmrEF, and HFrEF  
- Dual SGLT2i/SGLT1i therapy in HF  
- Non‑steroidal selective mineralocorticoid receptor antagonists (MRA) in HF  
- Angiotensin receptor–neprilysin inhibition (ARNi) in pre‑HF (stage B) and HFrEF  
- Pulmonary hypertension management (post‑ and precapillary)  
- Fibrosis‑targeted therapies (e.g., pirfenidone) in HFpEF  
- Potassium binders to optimize guideline‑directed medical therapy (GDMT)  
- Blood pressure targets in established HF and hypertension  
- Electrolyte management (hyper‑/hypokalemia) in HF  
- Peripartum cardiomyopathy (cause and targeted therapies)  
- Antioxidants, polyunsaturated fatty acids (PUFA) for atrial fibrillation risk in HF  
- Advanced screening strategies for HF (cost‑effectiveness, risk prediction)  
- Precision medicine/genetic testing in HF management  
- Integrated systems biology models for HF diagnosis, prognosis, and therapy targeting.

Page 91 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure with improved ejection fraction (HFimpEF)  
- Ventricular tachyarrhythmias  
- His‑bundle pacing  
- Multisite pacing  
- Cardiac contractility modulation  
- Vagal nerve stimulation  
- Autonomic modulation  
- Renal denervation  
- Splanchnic nerve ablation  
- Interatrial shunt  
- Pericardiectomy  
- Baroreceptor stimulation  
- Neuromodulation  
- Tricuspid regurgitation  
- Mechanical circulatory support (MCS)  
- Cardiac transplantation  
- Percutaneous interventions  
- Transcatheter aortic valve implantation (TAVI)  
- MitraClip (transcatheter mitral valve repair)  
- Tricuspid valve intervention  
- Valvular heart disease (VHD)  
- Chronic kidney disease (CKD)  
- Obesity  
- Diabetes mellitus  
- Depression  
- Cognitive disorders  
- Iron deficiency  
- Pulmonary artery pressure monitoring catheter  
- Remote monitoring  
- Telehealth  
- Digital health  
- Artificial intelligence (AI)  
- Adaptive trials  
- Umbrella trials  
- Basket trials  
- Machine‑learning‑based trials  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Sodium‑glucose cotransporter‑1 inhibitors (SGLT1i)  
- Angiotensin receptor‑neprilysin inhibitor (ARNi)  
- Mineralocorticoid receptor antagonist (MRA)  
- Polyunsaturated fatty acids (PUFA)  
- Guideline‑directed medical therapy (GDMT)  
- Patient‑reported outcomes  
- Quality of life (QOL)  
- Left ventricle (LV)  
- Right ventricle (RV)

Page 92 Extracted Terms:
- Heart Failure (HF)  
- Patient‑Reported Outcomes (PROs)  
- Health‑Related Quality of Life (QOL)  
- Kansas City Cardiomyopathy Questionnaire (KCCQ)  
- Minnesota Living with Heart Failure Questionnaire (MLHFQ)  
- PROMIS‑Plus‑HF (Patient‑Reported Outcomes Measurement Information System‑Plus‑Heart Failure)  
- New York Heart Association (NYHA) Functional Classification  
- Cardiopulmonary Exercise Test (CPET)  
- 6‑Minute Walk Test  
- Hospitalization (HF‑related)  
- Mortality (HF‑related)  
- Symptom Burden  
- Prognosis (HF)  
- Diuretic Escalation (HF therapy)  
- Medical Therapy Uptitration (HF)  
- Guideline‑Recommended Therapies (mortality benefit)  
- Population Health Management (HF risk stratification)  
- Routine Patient‑Reported Health Status Assessment  
- Clinical Outcomes (HF)  
- Functional Status (HF)  
- Quality of Treatment Decisions (HF)  
- Healthcare System Data Burden (HF assessment)  
- Evidence Gaps in HF Management  
- Future Research Directions (HF)  
- ACC/AHA/HFSA Heart Failure Guideline (HF)

Page 93 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Heart failure  
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Valvular heart disease  
- Coronary artery disease  
- Coronary artery revascularization  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass graft (CABG) surgery  
- Clinical practice guidelines  
- ACC/AHA guideline  
- AHA/ACC/HFSA Heart Failure Guideline  
- HFSA (Heart Failure Society of America) guideline  
- SCAI (Society for Cardiovascular Angiography and Interventions) guidelines  
- ACCF/AHA guideline  
- Cardiovascular disease management  
- Heart failure management  
- Valvular disease management  
- Coronary disease management  
- Cardiovascular health  
- Heart disease terminology  


These terms capture the main clinical conditions, procedural interventions, and guideline frameworks discussed in the provided excerpt.

Page 94 Extracted Terms:
Heart Failure  
ST‑elevation myocardial infarction (STEMI)  
Myocardial infarction  
Hypertrophic cardiomyopathy  
Atrial fibrillation  
Hypertension / high blood pressure  
Blood cholesterol / dyslipidemia  
Atherosclerotic cardiovascular disease / coronary artery disease  
Stable ischemic heart disease  
Cardiovascular risk assessment  
Cardiac amyloidosis  
Heart rhythm abnormalities (arrhythmia)  
Device‑based cardiac therapy (e.g., pacemaker, ICD)  
Post‑cardiac arrest care  
Cardiopulmonary resuscitation (CPR)  
Emergency cardiovascular care  
Low‑risk chest pain evaluation  
Diabetes‑related cardiovascular prevention  
Secondary prevention in atherosclerotic disease  
Primary prevention of cardiovascular disease  
Cardiovascular functional class (e.g., NYHA)  
New York Heart Association (NYHA) classification  

Page 95 Extracted Terms:
- Heart failure (HF)  
- Left ventricular ejection fraction (LVEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with recovered left ventricular ejection fraction (HFrecEF)  
- Dilated cardiomyopathy  
- Wild‑type transthyretin cardiac amyloidosis  
- Light‑chain amyloidosis  
- Congestion (clinical congestion, congestion on physical exam)  
- Volume overload  
- Loop diuretic dose  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Spironolactone  
- Dobutamine infusion (chronic dobutamine)  
- Milrinone infusion  
- Implantable cardioverter‑defibrillator (ICD) shocks  
- Mortality (all‑cause, HF‑specific, short‑ and long‑term)  
- Hospitalization and readmission (rehospitalization)  
- Physical examination findings (weight change, exam signs of congestion)  
- Exercise echocardiography  
- Cardiac hemodynamics (exercise hemodynamics)  
- H2F‑PEFF model (diagnostic algorithm)  
- HFA‑PEFF diagnostic algorithm (Heart Failure Association – European Society of Cardiology)  
- ESC guidelines (European Society of Cardiology)  
- ACCF/AHA guideline (American College of Cardiology Foundation/American Heart Association)  
- AHA/ACC/HFSA guideline (American Heart Association/American College of Cardiology/Heart Failure Society of America)  
- Heart Failure Society of America (HFSA)  
- Heart Failure Association (HFA) of the European Society of Cardiology (ESC)  
- EU‑FP7 MEDIA study group (diastolic stress tests)  
- American Heart Association (AHA)  
- National trends in HF hospitalization and readmission  
- Temporal trends in HF incidence and mortality  
- Epidemiology of HF, HFrEF, and HFpEF  
- Race and ethnicity in HF outcomes  
- Cardiac‑inherited disease (family history approach)  
- Epidemiological studies (Virani, Heidenreich, Dunlay, etc.)  
- Clinical assessment and prognostic indicators (congestion, weight loss, diuretic dose, ICD shocks)    
- Diagnostic algorithm for HF classification according to LVEF  
- Acute and chronic heart failure diagnosis guidelines  
- Predictive model for HFpEF (e.g., H2F‑PEFF).  

Page 96 Extracted Terms:
- Heart failure  
- Elevated jugular venous pressure  
- Third heart sound (S3)  
- Hemodynamics  
- Advanced heart failure  
- Bendopnea  
- Valsalva maneuver (biomarker)  
- Cardiac amyloidosis  
- Transthyretin cardiac amyloidosis (ATTR)  
- Transthyretin amyloid (ATTR) subtype  
- Dilated cardiomyopathy  
- Restrictive cardiomyopathy  
- Sarcoid cardiomyopathy (cardiac sarcoidosis)  
- Myocarditis  
- Inflammatory cardiomyopathy  
- Peripartum cardiomyopathy  
- Takotsubo (stress) cardiomyopathy  
- Alcohol‑induced cardiac toxicity  
- Cocaine‑associated cardiomyopathy  
- Methamphetamine‑associated cardiomyopathy  
- Anthracycline cardiotoxicity  
- Troponin I (cardiac biomarkers)  
- N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP)  
- B‑type natriuretic peptide (BNP)  
- Left ventricular dysfunction (ischemic)  
- Ischemic cardiomyopathy  
- Cardiovascular toxicity (due to cancer therapy)  
- Cardiovascular complications of cancer therapy  
- Cardiorheumatology (cardiac involvement in systemic rheumatic disease)  
- Thyroid hormones and cardiovascular disease  
- Heart failure in type 2 diabetes mellitus  
- Pheochromocytoma‑associated cardiomyopathy  
- Acromegaly‑associated heart failure  
- Obesity paradox in heart failure  
- Genotype and phenotype of cardiomyopathies  
- Mechanical circulatory support (bridge‑to‑transplant)  
- Heart transplantation outcomes in cardiomyopathy  
- Acute COVID‑19 cardiovascular syndrome  
- Biomarkers for risk stratification in heart disease  
- Diagnostic and treatment strategies for specific dilated cardiomyopathies  
- Clinical characteristics and management of Chagas cardiomyopathy  
- Current evidence and future directions in myocarditis and inflammatory cardiomyopathy  

(Each term represents a key concept or condition related to heart disease extracted from the guideline text.)

Page 97 Extracted Terms:
- Heart failure  
- Acute heart failure  
- Decompensated heart failure (ADHF)  
- Chronic heart failure  
- Advanced heart failure  
- Reduced ejection fraction (HFrEF)  
- Left ventricular failure (LVF)  
- Natriuretic peptides  
- B‑type natriuretic peptide (BNP)  
- N‑terminus pro‑BNP (NT‑proBNP)  
- Amino‑terminal pro‑BNP (NT‑proBNP)  
- High‑sensitivity troponin T (hs‑TnT)  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Galectin‑3  
- Soluble ST2 (sST2)  
- Growth differentiation factor‑15 (GDF‑15)  
- Obesity‑related suppression of BNP  
- Atrial fibrillation as a comorbidity in HF  
- Renal dysfunction in heart failure  
- Congestive heart failure  
- Diagnostic accuracy of BNP assays  
- Prognostic value of BNP/NT‑proBNP ratios  
- Biomarker‑guided therapy  
- Rapid bedside BNP testing  
- Emergency department decision‑making in HF  
- Discharge risk scoring models (ELAN‑HF, ESCAPE)  
- Readmission prediction for heart failure  
- Mortality prediction in HF patients  
- Troponin‑based rule‑out of acute cardiac insufficiency (TACIT)

Page 98 Extracted Terms:
- Heart failure  
- Dilated cardiomyopathy  
- Left ventricular dysfunction  
- Right ventricular dysfunction  
- Ventricular remodeling  
- Ischemic heart disease  
- Myocardial infarction  
- Cardiac amyloidosis  
- Anderson‑Fabry disease  
- Arrhythmogenic right ventricular dysplasia/cardiomyopathy  
- Myocardial viability  
- Hibernating myocardium  
- Implantable cardioverter‑defibrillator (ICD)  
- Wearable cardioverter‑defibrillator (WCD)  
- B‑type natriuretic peptide (BNP)  
- NT‑proBNP (N‑terminal pro‑B‑type natriuretic peptide)  
- Echocardiography (2‑D, 3‑D, Doppler)  
- Cardiovascular magnetic resonance (CMR)  
- T1 mapping (non‑contrast)  
- T2* MRI for myocardial iron overload  
- Computed tomography (CT) cardiac imaging  
- Low‑dose dual‑source CT for ventricular function  
- Cardiac CT coronary angiography (CTA)  
- Radionuclide ventriculography  
- Dobutamine stress echocardiography  
- Myocardial perfusion imaging (MPI)  
- Positron emission tomography (PET) with FDG  
- Cardiac structural assessment  
- Cardiac functional assessment  
- Genetic evaluation of cardiomyopathy  
- Family history / pedigree analysis  
- Genetic variation in dilated cardiomyopathy  
- Titin truncations  
- Arrhythmic phenotypes (genetic basis)  
- Non‑invasive global and regional ventricular function  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular volumes  
- Myocardial mass quantification  
- Appropriate use criteria for multimodality imaging (ACC/AHA)  
- Coronary artery disease (CAD) in heart failure  
- Revascularization benefits (PCI, CABG)  
- Myocardial hibernation  
- Myocardial ischemia detection  
- Cardiac mortality assessment  
- Prognostic implications of imaging findings  
- Cardiovascular imaging registry (EuroCMR)  

These terms capture the major concepts related to heart disease discussed throughout the provided guidelines and referenced studies.

Page 99 Extracted Terms:
- Heart Failure  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Acute Decompensated Heart Failure  
- Congestive Heart Failure  
- Left Ventricular Dysfunction  
- Left Ventricular Mass  
- Left Ventricular Filling Pressures  
- Systolic Function  
- Diastolic Function  
- Systolic Dysfunction  
- Diastolic Dysfunction  
- Ejection Fraction  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular Strain  
- Global Longitudinal Strain  
- Left Ventricular Longitudinal Strain  
- Ventricular Volumes  
- Ventricular Size  
- Ventricular Remodeling  
- Ventricular Function  
- Pulmonary Congestion  
- Functional Mitral Regurgitation  
- Myocardial Infarction  
- Coronary Artery Disease  
- Myocardial Scar  
- Dilated Cardiomyopathy  
- Nonischemic Cardiomyopathy  
- Cardiac Sarcoidosis  
- Myocardial Fibrosis  
- Diffuse Myocardial Fibrosis  
- Extracellular Matrix Expansion  
- Late Gadolinium Enhancement (LGE)  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Cardiovascular Magnetic Resonance  
- Delayed‑Enhancement Magnetic Resonance  
- CMR Mapping  
- Cardiac Resynchronization Therapy (CRT)  
- Carvedilol  
- Enalapril  
- Empagliflozin  
- Spironolactone  
- B‑type Natriuretic Peptide (BNP)  
- Hand‑Carried Echocardiography  
- Point‑of‑Care Lung Ultrasound  
- Echocardiographic Diastolic Parameters  
- Cardiac Chamber Quantification  
- SPECT Perfusion Imaging  
- Cardiac Imaging  
- Cardiac Ultrasound  
- Heart Failure Guidelines  
- Left Ventricular Longitudinal Strain (LVLS)  
- Right Ventricular Dysfunction  
- Left Ventricular Function Recovery  
- Ejection Fraction Recovery  
- Cardiovascular Outcomes  
- Prognostic Indicators  
- Myocardial Inflammation  
- Myocardial Fibrosis Assessment  
- Ventricular Scar Detection  
- Cardiomyopathy Etiology  
- Cardiac Magnetic Resonance Contrast  
- Cardiovascular Magnetic Resonance Techniques  
- Cardiac Magnetic Resonance in Acute Heart Failure  
- Cardiac Magnetic Resonance in Chronic Heart Failure  
- Echocardiographic Prognostic Implications  
- Cardiac MRI Myocardial Mapping

These terms capture the key heart‑disease concepts, diagnostic and therapeutic modalities, and prognostic indicators referenced within the provided clinical guideline text.

Page 100 Extracted Terms:
**Key terms related to heart disease**

- Heart failure  
- Chronic heart failure  
- Acute decompensated heart failure  
- Non‑ischemic dilated cardiomyopathy (non‑ischemic heart failure)  
- Ischemic cardiomyopathy / ischemic left‑ventricular dysfunction  
- Left‑ventricular dysfunction / ejection fraction  
- Cardiac amyloidosis / transthyretin amyloid cardiomyopathy  
- Congestive heart failure  
- Coronary artery disease / ischemic heart disease  
- Coronary revascularization / coronary artery bypass grafting  
- Pulmonary artery catheterization / pulmonary artery pressure monitoring  
- Pulmonary hypertension  
- Remote patient monitoring / telemonitoring  
- CardioMEMS implantable pulmonary‑artery pressure sensor  
- Implantable cardioverter‑defibrillators (ICD)  
- Biventricular defibrillators (CRT‑D)  
- Cardiac magnetic resonance (CMR) imaging  
- Late gadolinium enhancement (LGE)  
- Endomyocardial biopsy  
- Cardiovascular imaging / cardiovascular magnetic resonance  
- Appropriate use criteria (AUC) for cardiac imaging and revascularization  
- Randomized controlled trial (RCT)  
- Non‑invasive imaging-assisted management  
- Structured telephone support / telemedicine alerts  
- Cost‑effectiveness analysis  
- Clinical outcomes (mortality, hospitalization)  
- New York Heart Association (NYHA) class  
- Exercise capacity / functional capacity testing  

These terms capture the principal disease entities, diagnostic technologies, therapeutic interventions, and outcome measures discussed in the cited guidelines and studies.

Page 101 Extracted Terms:
**Key terms related to heart disease found in the text**

- Heart failure  
- Systolic heart failure  
- Preserved ejection fraction (HFpEF)  
- Left ventricular dysfunction  
- Cardiopulmonary exercise testing (CPET)  
- Peak oxygen consumption (VO₂ peak)  
- Six‑minute walk test (6MWT)  
- Beta‑blocker therapy  
- Cardiac transplantation  
- Mechanical circulatory support  
- Heart failure risk scoring  
- Seattle Heart Failure Model  
- GWTG‑heart failure risk score  
- MAGGIC (Meta‑analysis Global Group in Chronic Heart Failure) risk calculator  
- ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model  
- HF‑ACTION predictive risk score  
- GUIDE‑IT predictive model  
- I‑PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction) study  
- Apolipoprotein A‑1  
- High‑sensitivity C‑reactive protein (hs‑CRP)  
- N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP)  
- New York Heart Association (NYHA) functional classification  
- Functional capacity  
- Mortality  
- Morbidity  
- Readmission  
- Dyspnea  
- Inspiratory muscle strength  
- Blood pressure (hypertension)  
- Coronary artery disease  
- Pulmonary hypertension  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2‑i) (mentioned in broader guideline context)

Page 102 Extracted Terms:
- Heart failure  
- Hypertension  
- Blood pressure  
- Left ventricular dysfunction  
- Left ventricular ejection fraction  
- Atherosclerosis  
- Coronary artery disease  
- Myocardial infarction  
- Ischemic heart disease  
- Diabetes mellitus type 2  
- SGLT2 inhibitor  
- ACE inhibitor  
- Angiotensin II receptor blocker  
- Beta blocker  
- Diuretic  
- Statin  
- Antiplatelet therapy  
- Anticoagulant therapy  
- Lifestyle modification  
- Physical activity  
- Sedentary time  
- Mediterranean diet  
- DASH diet  
- Natriuretic peptide  
- NT‑proBNP  
- Risk prediction  
- Framingham risk score  
- ASCVD risk estimate  
- Risk model  
- Heart‑failure prevention  
- Systolic blood pressure  
- Isolated systolic hypertension  
- Heart failure with preserved ejection fraction  
- Heart failure with reduced ejection fraction  
- Left‑ventricular remodeling  
- Cardiovascular death  
- Cardiovascular morbidity  
- Heart‑failure hospitalization  
- Cardiac structure  
- Cardiac function  
- Heart‑failure guidelines  
- AHA/ACC/HFSA guideline  
- ACC/AHA guideline  
- Hypertension guideline  

Page 103 Extracted Terms:
- Atherosclerotic heart disease  
- Aortic stenosis  
- ARNI (angiotensin receptor‑neprilysin inhibitor)  
- Angiotensin‑converting enzyme inhibitor (ACEI)  
- Angiotensin‑II receptor blocker (ARB)  
- Beta‑blocker  
- Blood cholesterol management  
- Cardiac remodeling  
- Cardiomyopathy, idiopathic dilated  
- Cardiovascular mortality  
- Constrictive pericarditis  
- Coronary artery bypass grafting (CABG)  
- Coronary artery disease (CAD)  
- Coronary artery revascularization  
- Diastolic dysfunction  
- Diastolic heart failure (HFpEF)  
- Diastolic dysfunction, asymptomatic  
- Diltiazem, calcium‑channel blocker  
- Drug‑induced heart failure  
- End‑organ damage, cardiac  
- Ejection fraction (EF)  
- Early aldosterone blockade  
- Early eplerenone therapy  
- Heart failure, stage B (pre‑symptomatic)  
- Heart failure, stage C (symptomatic)  
- Heart failure, stage D (advanced)  
- Heart failure, with reduced ejection fraction (HFrEF)  
- Heart failure, with preserved ejection fraction (HFpEF)  
- Heart failure, with mid‑range ejection fraction (HFmrEF)  
- Heart failure, prognostic markers  
- Heart failure, secondary to myocardial infarction  
- Heart failure, type 2 diabetes mellitus  
- Heart function tests  
- Heart transplantation candidates  
- Heart transplant  
- Heterogeneous myocardial infarction outcomes  
- Hemodynamic monitoring  
- Hypertrophic cardiomyopathy  
- Hypertrophic cardiomyopathy  
- Idiopathic dilated cardiomyopathy  
- Left ventricular dysfunction, asymptomatic  
- Left ventricular remodeling  
- Left ventricular strain, speckle‑tracking echocardiography  
- Left ventricular systolic dysfunction  
- Left ventricular diastolic dysfunction  
- Longitudinal strain by echocardiography  
- Major adverse cardiovascular events (MACE)  
- Metabolic syndrome, heart disease risk  
- Myocardial infarction (MI)  
- Myocardial infarction, ST‑elevation (STEMI)  
- Myocardial infarction, non‑ST‑elevation (NSTEMI)  
- Myocardial infarction, acute  
- Myocardial infarction, chronic  
- Myocardial infarction outcome measures  
- Myocardial infarction, evidence‑based interventions  
- Myocardial infarction, revascularization outcomes  
- Multicenter clinical trials (e.g., CAPRICORN, ALBATROSS)  
- New York Heart Association (NYHA) functional classification  
- Non‑ischemic cardiomyopathy  
- Oral glucose‑lowering agents in heart disease  
- Pioglitazone  
- Predictors of heart failure progression  
- Prognostic implications of left‑ventricular strain  
- Prevention of heart failure  
- Primary prophylactic implantable cardio‑electrical defibrillator (ICD) implantation  
- Primary percutaneous coronary intervention (PCI)  
- Prognosis of asymptomatic left‑ventricular dysfunction  
- Prognostic significance of heart failure stages  
- Renin–angiotensin–aldosterone system (RAAS) blockade  
- Risk of progression from left‑ventricular dysfunction to overt heart failure  
- Rosiglitazone  
- Systolic heart failure  
- Tachycardia‑induced cardiomyopathy  
- Thoracic aortic disease  
- Thiazolidinediones (TZDs)  
- Transcatheter aortic valve replacement (TAVR)  
- Treatment guidelines for acute coronary syndromes (ACS)  
- Treatment guidelines for ST‑elevation myocardial infarction (STEMI)  
- Treatment guidelines for non‑ST‑elevation acute coronary syndromes (NST‑ACS)  
- Treatment of asymptomatic left‑ventricular dysfunction  
- Treatment of early post‑myocardial infarction heart failure  
- Treatment of heart failure with preserved ejection fraction (HFpEF)  
- Treatment of heart failure with mid‑range ejection fraction (HFmrEF)  
- Treatment of post‑infarction remodeling  
- Treatment of heart failure, multi‑drug strategies  
- Treatment of diabetes in heart failure  
- Treatment of metabolic disorders in heart disease  
- Time‑to‑event analysis in cardiovascular trials  
- Valvular heart disease, severe aortic stenosis  
- Vasodilator therapy, nitrates  
- Ventricular enlargement after myocardial infarction  
- Ventricular remodeling, left and right  
- Ventricular dysfunction, systolic and diastolic  
- Vascular risk factors in heart disease  
- Vasodilator therapy (e.g., verapamil)  
- Wall‑stress reduction strategies  
- Worsening heart failure symptoms  
- Advanced heart failure interventions  
- Anaphylactic reactions to beta‑blockers  
- Antithrombotic therapy post‑MI  
- Apical aneurysm after MI  
- Arrhythmia management in heart failure  
- Aortic valve repair and replacement  
- Blood pressure control in heart disease  
- Cardiac arrest resuscitation guidelines  
- Cardiac imaging modalities (MRI, CT, PET)  
- Cardiac output monitoring  
- Cardio‑pulmonary exercise testing  
- Cardio‑vascular exercise guidelines  
- Cardio‑vascular disease burden  
- Cardio‑vascular disease epidemiology  
- Cardio‑vascular disease prevention strategies  
- Cardio‑vascular disease risk scores (e.g., Framingham)  
- Cardio‑vascular rehabilitation  
- Cardio‑vascular surgery indications  
- Cardio‑vascular outcomes in diabetes studies  
- Cardio‑vascular outcomes in thiazolidinedione trials  
- Cardio‑vascular outcomes in ACEI/ARB trials  
- Cardio‑vascular outcomes in beta‑blocker trials  
- Cardio‑vascular outcomes in calcium channel blocker trials  

(Feel free to trim or refine the list to your specific focus area.)

Page 104 Extracted Terms:
- Heart failure  
- Stable ischemic heart disease  
- Coronary artery bypass graft surgery  
- Valvular heart disease  
- Congenital heart disease  
- Self‑care support in heart failure  
- Multidisciplinary interventions for heart failure  
- Structured telephone support / telemonitoring  
- Self‑management in heart failure patients  
- Medication adherence interventions  
- Influenza vaccination in heart failure  
- SARS‑CoV‑2 vaccine effectiveness (high‑risk population)  
- Cardiovascular disease / cardio‑vascular outcomes  
- Stroke prevention in cardiovascular disease  
- Depression and heart failure outcomes  
- Social relationships and heart failure survival  
- Frailty in chronic heart failure  
- Health literacy in heart failure patients  
- Team‑based care for cardiac comorbidities  
- Advanced heart failure management  
- mHealth education interventions for heart failure  
- Patient‑centered transitional care for hospitalized heart failure  
- Chronic heart failure (congestive heart failure)  
- Cardiac rehabilitation  
- Heart failure mortality & readmission rates  
- Cardiovascular outcomes in heart failure populations  

Page 105 Extracted Terms:
- Heart failure
- Chronic heart failure
- Decompensated heart failure
- Acute heart failure
- Heart failure with reduced ejection fraction
- Heart failure with preserved ejection fraction
- Cardiac remodeling
- Coronavirus disease‑2019 (COVID‑19)
- Pre‑eclampsia
- Post‑discharge risk
- Cognitive impairment
- Dementia
- Depression
- Substance abuse
- Frailty
- Food insecurity
- Housing insecurity
- Homelessness
- Socioeconomic inequities
- Intimate partner violence
- Elder abuse
- Abuse of vulnerable adults
- Limited English proficiency
- Health literacy
- Social isolation
- Dietary sodium restriction
- Salt restriction
- Fluid restriction
- Low‑sodium diet
- Moderate‑sodium diet
- Mediterranean diet
- Nutritional status
- Micronutrient supplementation
- Iron deficiency
- Oral iron repletion
- Thiamin supplementation
- Zinc deficiency
- Vitamin D supplementation
- Micronutrient deficiency
- Sodium intake
- Sodium‑restricted diet
- Cardiovascular disease
- Cardiometabolic disease
- Coronary artery disease
- Percutaneous coronary intervention
- Cardiac blood flow velocity
- Clinical outcomes
- Readmission burden
- Home‑delivered meals
- Food insecurity screeners
- Cardiovascular health equity
- Primary prevention
- Secondary prevention
- Dietary sodium content
- SODIUM‑HF trial
- Prohibit trial
- MED‑AHF study
- IRONOUT HF trial
- Micronutrient‑deficiency screening
- Fluid and sodium restriction protocols
- Management of heart failure guidelines  


Page 106 Extracted Terms:
- Heart Failure (HF)  
- Chronic Heart Failure  
- Systolic Heart Failure  
- Diastolic Heart Failure  
- Reduced Ejection Fraction (HFrEF)  
- Preserved Ejection Fraction (HFpEF)  
- Cardiac Rehabilitation  
- Exercise Training / Exercise Prescription  
- Aerobic Interval Training  
- Resistance Exercise  
- Exercise Capacity  
- Endurance Exercise  
- Oxygen Uptake / Peak VO₂  
- Quality of Life  
- Diuretic Treatment  
- Loop Diuretics (e.g., Furosemide, Torsemide, Torasemide)  
- Thiazide‑type Diuretics  
- Sodium Retention  
- Diuretic Resistance  
- Cardiorenal Syndrome  
- Diuretic Synergism  
- Renin–Angiotensin–Aldosterone System (RAAS) Inhibition  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin Receptor Blockers (ARB)  
- Angiotensin Receptor‑Neprilysin Inhibitors (ARNi)  
- Sacubitril/Valsartan (Entresto)  
- Enalapril  
- Aortic Stiffness  
- Endothelial Function  
- Arterial Stiffness  
- Cardiac Reverse Remodeling  
- Diastolic Function  
- Congestive Heart Failure (CHF)  
- Acute Decompensated Heart Failure (ADHF)  
- Hospital Discharge / Early After Discharge Management  
- Bioavailability / Pharmacokinetics / Pharmacodynamics of Diuretics  
- Cardiorespiratory Training  
- Clinical Outcomes  
- Meta‑analysis / Systematic Review  
- Randomized Controlled Trial (RCT)  
- Clinical Guidelines (AHA/ACC/HFSA, Dutch Practice Guideline)  
- Heart Failure-ACTION Study  
- ExTraMATCH Study  
- Ex‑DHF Pilot Study  
- 3T Trial (loop diuretic resistance)  
- TRANSITION Study (sacubitril/valsartan initiation)  
- TORIC Study (torasemide)  
- Cooperative North Scandinavian Enalapril (CONSENSUS) Study  

These terms capture the key heart‑disease concepts and interventions mentioned in the provided guideline excerpt.

Page 107 Extracted Terms:
**Heart‑disease related terms extracted from the text**  

1. Heart failure (congestive heart failure)  
2. Reduced left ventricular ejection fraction  
3. Left ventricular dysfunction  
4. Myocardial infarction  
5. Angiotensin‑converting enzyme (ACE) inhibitor  
6. Enalapril  
7. Lisinopril  
8. Captopril  
9. Ramipril  
10. Trandolapril  
11. Valsartan  
12. Losartan  
13. Telmisartan  
14. ARNI (angiotensin‑receptor‑neprilysin inhibitor)  
15. Sacubitril/valsartan (LCZ‑696, LCZ‑696)  
16. Omapatrilat  
17. β‑blocker (beta‑blocker)  
18. Metoprolol (CR/XL, extended‑release)  
19. Bisoprolol  
20. Carvedilol  
21. Neprilysin inhibitor  
22. Dual‑acting inhibitor of angiotensin II receptor and neprilysin  
23. Angioedema (ACE‑inhibitor‑associated)  
24. Renin‑angiotensin‑aldosterone system (RAAS)  
25. Mortality and morbidity  
26. Clinical outcomes (hospitalisation, survival)  
27. Cost‑effectiveness  
28. Randomised clinical trial  
29. Pharmacologic management of heart failure  
30. Left ventricular systolic dysfunction  
31. Left ventricular mid‑range preserved ejection fraction  
32. Renin‑angiotensin‑inhibitor safety  
33. Blood‑pressure reduction  
34. Antihypertensive therapy  
35. Cardiovascular events  
36. Vascular events  
37. Pharmacogenomics (XPNPEP2 polymorphism)  
38. Acute myocardial infarction with heart failure  
39. Chronic heart failure  
40. Hypertension  

*(List provided as requested format – a simple list of terms.)*

Page 108 Extracted Terms:
- Heart failure  
- Metoprolol CR/XL  
- MERIT‑HF  
- β‑blockers  
- Atrial fibrillation  
- Nebivolol  
- SENIORS  
- Bucindolol  
- Carvedilol  
- Metoprolol  
- COMET  
- Bisoprolol  
- Enalapril  
- CIBIS III  
- Hydrocortisone  
- Spironolactone  
- Mineralocorticoid receptor antagonists (MRAs)  
- Aldactone (spironolactone)  
- Eplerenone  
- Eplerenone Post‑Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)  
- Angiotensin‑neprilysin inhibition (ARNI)  
- Sacubitril/valsartan  
- RLY5016 (polysorbate potassium binder)  
- Sodium zirconium cyclosilicate (ZS‑9)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Dapagliflozin  
- Empagliflozin  
- Canagliflozin  
- Sotagliflozin  
- DAPA‑HF trial  
- EMPEROR‑Reduced  
- Hydralazine  
- Isosorbide dinitrate  
- Hydralazine‑isosorbide dinitrate (H‑ISDN)  
- Hydralazine‑isosorbide dinitrate for black patients with heart failure  
- n‑3 polyunsaturated fatty acids (omega‑3)  
- GISSI‑HF trial  
- Acute myocardial infarction  
- Left ventricular dysfunction  
- Left ventricular systolic dysfunction  
- Reduced ejection fraction (HFrEF)  
- Chronic congestive heart failure  
- Cardiovascular hospital admission  
- Mortality  
- Hyperkalemia  
- Cost‑effectiveness  
- Veterans Administration Cooperative Study (VACS)  
- Get With The Guidelines‑Heart Failure registry  

*(These terms encompass clinical conditions, pharmacologic agents, therapeutic strategies, trials, and outcome measures relevant to heart disease.)*

Page 109 Extracted Terms:
- Heart Failure  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Congestive Heart Failure (CHF)  
- Left Ventricular Dysfunction  
- Ventricular Dysfunction  
- Myocardial Infarction (MI)  
- Acute Myocardial Infarction  
- Coronary Artery Disease (CAD)  
- Sinus Rhythm  
- Hypertriglyceridemia  
- Hyperkalemia  
- Dyskinesia (mentioned in context of sodium zirconium cyclosilicate)  
- Antithrombotic Therapy  
- Anticoagulation (Warfarin)  
- Aspirin Therapy  
- Clopidogrel Therapy  
- Rivaroxaban Therapy  
- Calcium Channel Blockers (Amlodipine, Verapamil, Diltiazem)  
- Sodium Zirconium Cyclosilicate (ZS‑9)  
- Mineralocorticoid Receptor Antagonists  
- Digoxin  
- Omega‑3 Polyunsaturated Fatty Acids  
- icosapent ethyl  
- Vitamin D Supplementation  
- Vitamin E Supplementation  
- Coenzyme Q10  
- Thiazolidinediones (Rosiglitazone, Pioglitazone, Ipratropium‑related agents)  
- Dipeptidyl Peptidase‑4 (DPP‑4) Inhibitors (Saxagliptin, Alogliptin)  
- Dronedarone  
- Flecainide  
- Encainide  
- D‑sotalol  
- Atrial arrhythmia‑related drugs (noting arrhythmia suppression trials)  
- Cardiac Arrhythmia Suppression Trial (CATS)  
- SWORD (Survival With Oral d‑Sotalol)  
- SAVOR‑TIMI 53 (DPP‑4 inhibitor outcomes)  
- EXAMINE (Alogliptin outcomes)  
- AHA/ACC/HFSA Heart Failure Guideline  
- GISSI‑Prevenzione Trial (n‑3 fatty acids & Vitamin E)  
- REDUCE‑IT Trial (icosapent ethyl)  
- WATCH Trial (Warfarin & antiplatelet therapy)  
- PEARL‑HF Trial (RLY5016 potassium binder)  
- HARMONIZE Trial (Sodium zirconium cyclosilicate)  
- GISSI‑Prevenzione Trial (post‑MI outcomes)  
- VITAL‑Heart Failure Trial (Vitamin D supplementation)  
- Q‑SYMBIO Trial (Coenzyme Q10)  
- Multicenter Diltiazem Post‑Infarction Trial  
- Danish Verapamil Infarction Trial (DAVIT II)  
- GIST (not present in list)  

(Any duplicate or overlapping terms have been merged; the list captures all distinct concepts tied to heart‑disease pathophysiology, risk, or therapy that appear in the provided text.)

Page 110 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Heart failure (HF)  
- Congestive heart failure (CHF)  
- Chronic heart failure (CHF)  
- Systolic (reduced‑ejection‑fraction) heart failure  
- Diastolic (preserved‑ejection‑fraction) heart failure  
- Left‑ventricular ejection fraction (LVEF)  
- Renin–angiotensin–aldosterone system (RAAS)  
- β‑blockers (e.g., metoprolol, carvedilol, bisoprolol)  
- Angiotensin‑converting‑enzyme inhibitors (ACEi) → enalapril, lisinopril, CIBIS‑II drug  
- Angiotensin‑II receptor blockers (ARBs)  
- Aldosterone antagonists → spironolactone, eplerenone  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
  - Dapagliflozin  
  - Empagliflozin  
- Neurohormonal modulation (GDMT)  
- Combination therapy (isosorbide dinitrate + hydralazine)  
- Anti‑arrhythmic drugs → amiodarone, dofetilide  
- Calcium‑channel blockers → amlodipine  
- Angiotensin‑neprilysin inhibitors (ARNI) → sacubitril/valsartan  
- Thyroid hormone replacement therapy (levothyroxine T4, triiodothyronine T3)  
- Hormonal therapies → growth hormone, testosterone  
- Nutraceuticals / supplements → coenzyme‑Q10, L‑carnitine, taurine, thiamine  
- Cardiac biomarkers → NT‑proBNP, BNP  
- Left‑ventricular dysfunction  
- Myocardial infarction (MI) / acute coronary syndrome (ACS)  
- Ventricular arrhythmias (sudden cardiac death risk)  
- Type 2 diabetes mellitus (T2DM) – interaction with HF medications  
- DPP‑4 inhibitors (saxagliptin, alogliptin, sitagliptin, linagliptin) – HF risk  
- Obesity / cachexia / nutritional status – HF risk factors  

These terms encapsulate the core concepts of cardiovascular pathology, therapeutic targets, and risk factors discussed in the cited clinical statements and guideline references.

Page 111 Extracted Terms:
- Heart failure  
- Chronic heart failure (CHF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular dysfunction  
- Left ventricular systolic dysfunction  
- Left ventricular ejection fraction (LVEF)  
- Congestive heart failure (CHF)  
- Atrial fibrillation (AF)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Non‑ischemic cardiomyopathy  
- β‑blocker therapy  
- Carvedilol  
- Captopril  
- Candesartan  
- Enalapril  
- Losartan  
- Valsartan  
- Aldosterone blockade (mineralocorticoid receptor antagonism)  
- Sodium‑glucose cotransporter‑2 inhibitor (SGLT₂‑i) therapy  
- Angiotensin‑converting enzyme inhibitor (ACE‑I)  
- Angiotensin receptor blocker (ARB)  
- Soluble guanylate cyclase stimulators  
- Vericiguat  
- Digoxin  
- Ivabradine  
- Cardiac resynchronization therapy (CRT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Transcatheter mitral‑valve repair (TMVR)  
- Mortality  
- Morbidity  
- Hospitalization  
- Clinical outcome  
- Quality of care  
- Drug‑tolerability  
- Dose‑response  
- Ejection fraction improvement  
- Ventricular remodeling  
- Left ventricular enlargement  
- Heart‑rate control  
- Vasodilator therapy  
- Neurohormonal blockade  
- Antihypertensive therapy  
- Chronic heart‑failure treatment guidelines  
- AHA/ACC/HFSA Heart Failure Guideline  
- DIG trial (Digitalis Investigation Group)  
- SHIFT trial (Ivabradine treatment)  
- BEAUTIFUL trial (Ivabradine in CAD with LV dysfunction)  
- PROVED trial (Digoxin withdrawal in CHF)  
- ATLAS study (Low vs high dose lisinopril)  
- HEAAL study (Losartan dose comparison)  
- SAVE study (Captopril after MI)  
- CHARM‑Overall program (Candesartan in CHF)  
- Valsartan Heart Failure Trial (VHT)  
- Vericiguat trial (Vericiguat in HFrEF)  
- Meta‑analysis studies  
- Randomized controlled trials (RCTs)

These terms capture the primary diseases, therapeutic agents, devices, clinical outcomes, and research/ guideline references discussed in the text.

Page 112 Extracted Terms:
- Heart Failure  
- Congestive Heart Failure  
- Dilated Cardiomyopathy  
- Non‑ischemic Cardiomyopathy  
- Ischemic Cardiomyopathy  
- Myocardial Infarction  
- Coronary Artery Disease  
- Ventricular Arrhythmias  
- Sudden Cardiac Death  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Cardiac Resynchronization Therapy (CRT)  
- Biventricular Pacing / Biventricular Pacemaker  
- Left Ventricular Systolic Dysfunction  
- Left Ventricular Ejection Fraction  
- QRS Morphology (e.g., Right Bundle Branch Block)  
- QRS Duration  
- Left Ventricular Remodeling  
- Right Bundle Branch Block  
- Symptomatic Heart Failure  
- Mild/Moderate Heart Failure  
- Asymptomatic Heart Failure  
- AV Nodal Ablation / Left Ventricular‑Based Cardiac Stimulation  
- Cost‑Effectiveness of Cardiac Devices  
- Genetic Risk in Arrhythmic/Dilated Cardiomyopathy  
- Risk Stratification for Sudden Cardiac Death  
- Multicenter Automatic Defibrillator Implantation Trial (MADIT)  
- Multicenter Un‑sustained Tachycardia Trial (MUST)  
- Sudden Cardiac Death in Heart Failure Trial (SCD‑HeFT)  
- COMPANION Trial  
- REVERSE Study  
- RAFT Study  
- CARE‑HF Trial  
- PAVE Study  
- HRS Expert Consensus on Arrhythmogenic Cardiomyopathy  
- ICD Cost‑Effectiveness  
- CRT Cost‑Effectiveness  
- QRS‑Based Outcome Prediction  
- Cardiovascular Endothelial Nitric Oxide Pathway (includes guanylate cyclase, cGMP)  
- Pharmacologic Antiarrhythmics (e.g., amiodarone, amiodarone vs ICD)  
- Heart‑Failure Pharmacology (implied by trials addressing ICD/CRT in patients with reduced EF)

Page 113 Extracted Terms:
**Key heart‑disease related terms (from the provided guideline text)**  
- AHA/ACC/HFSA Heart Failure Guideline  
- AHA/ACC/HRS guideline for ventricular arrhythmias & prevention of sudden cardiac death  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Ventricular arrhythmias  
- Sudden cardiac death (SCD)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Neurohormonal activation in heart failure  
- Baroreflex activation therapy (BAT)  
- Vagus nerve stimulation (VNS)  
- His‑bundle pacing (His‑SP) / His‑bundle correction  
- Biventricular (bi‑V) pacing  
- Cardiac contractility modulation (CCM)  
- Revascularization for coronary artery disease (CAD)  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Left‑main equivalent coronary artery disease  
- Ischemic cardiomyopathy  
- Left ventricular dysfunction / systolic dysfunction  
- Left ventricular remodeling  
- Mitral regurgitation (functional MR)  
- Valvular heart disease (mitral, aortic)  
- STICH trial (Surgical Treatment for Ischemic Heart Failure)  
- CABG Patch Trial, STICH, REVIVED‑BCIS2, ESH, NARROW‑CRT, LESSER‑EARTH, SPARE, COMPANION, etc. (study identifiers)  
- Cardiovascular outcome studies (e.g., CASS, STICH, REVIVED, ACC/AHA trials)  
- Implantable electrical interventions (e.g., multipoint pacing, non‑excitatory electrical impulses)  
- Coronary revascularization outcomes (e.g., survival advantage, quality‑of‑life, angina relief)  

These terms capture the principal diseases, interventions, therapies, and clinical studies discussed in the excerpt.

Page 114 Extracted Terms:
- Heart failure  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure with improved ejection fraction  
- Cardiomyopathy  
- Dilated cardiomyopathy  
- Left ventricular dysfunction  
- Systolic heart failure  
- Left ventricular ejection fraction  
- Left ventricular remodeling  
- Ventricular remodeling  
- Cardiac resynchronization therapy  
- Cardiac contractility modulation  
- β‑blocker therapy / β‑blockade  
- Renin‑angiotensin system inhibitors  
- Angiotensin receptor neprilysin inhibitor (ARNI)  
- Sacubitril/valsartan  
- Empagliflozin  
- Neurohormonal therapy  
- Cardiac rehabilitation  
- High‑intensity exercise‑based cardiac rehabilitation  
- Mitral regurgitation  
- Functional mitral regurgitation  
- Secondary mitral regurgitation  
- Proportionate functional mitral regurgitation  
- Disproportionate functional mitral regurgitation  
- Percutaneous mitral valve repair (TMR)  
- Surgical mitral valve repair  
- Transcatheter aortic valve replacement (TAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement  
- Aortic stenosis  
- Low‑gradient aortic stenosis  
- Low‑flow aortic stenosis  
- Aortic regurgitation  
- Severe aortic regurgitation  
- Valvular heart disease  
- Prosthetic valve  
- Aortic valve intervention  
- Aortic valve surgery  
- Hemodynamic response  
- Cardiac output  
- Pharmacologic treatment  
- Pericardial disease (implicit in heart failure context)

Page 115 Extracted Terms:
**Heart‑disease related terms extracted from the text**

1. Heart failure  
2. Heart failure with preserved ejection fraction (HFpEF)  
3. Heart failure with reduced ejection fraction (HFrEF)  
4. Left‑ventricular ejection fraction (LVEF)  
5. Ejection fraction (EF)  
6. Diastolic dysfunction / diastolic heart failure  
7. Systolic hypertension  
8. Hypertension / high blood pressure  
9. Myocardial infarction  
10. Atrial fibrillation  
11. Coronary artery disease  
12. Revascularisation (PCI/CABG)  
13. Cardiac rehabilitation  
14. β‑blockers (e.g., nebivolol, bisoprolol, digoxin‑related β‑blockade)  
15. Angiotensin‑converting enzyme inhibitors (ACE‑I)  
16. Angiotensin‑II receptor blockers (ARBs)  
17. Aldosterone antagonists (e.g., spironolactone, eplerenone)  
18. Spironolactone  
19. Empagliflozin (SGLT2 inhibitor)  
20. Sacubitril/valsartan (ARNI)  
21. Candesartan (ARB)  
22. Isosorbide mononitrate  
23. Phosphodiesterase‑5 inhibitors (e.g., sildenafil)  
24. Nebivolol  
25. Digoxin  
26. Brain natriuretic peptide (BNP)  
27. N‑terminal pro‑BNP (NT‑proBNP)  
28. Pleural effusion  
29. Clinical trials & studies:  
   - EMPEROR‑Preserved  
   - EMPEROR‑Reduced  
   - TOPCAT  
   - PARADIGM‑HF  
   - SPRINT  
   - CHARM‑Preserved  
   - SPRINT (intensive vs standard BP)  
   - ALLHAT  
   - PEP‑CHF  
   - Packer et al. EMPEROR‑Preserved (2021)  
   - Ather et al. (non‑cardiac comorbidities)  
   - Soloman et al. (PARADIGM‑HF)  
   - Zanchetti et al. (hypertension BP lowering)  
30. Anti‑hypertensive drugs (e.g., diuretics, antihypertensives)  
31. Endothelin system  
32. Renin‑angiotensin system  
33. Myocardial collagen turnover (diastolic HF evidence)  
34. Coronary microvascular endothelial inflammation  
35. Perindopril (in elderly HF)  

*(All terms above are directly referenced or implied within the provided guideline citations and are core concepts in contemporary heart‑disease management.)*

Page 116 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Heart failure (HF)  
- Preserved ejection fraction (HFpEF)  
- Reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF) – >40 %  
- Beta‑blockers  
- Renin‑angiotensin‑aldosterone system (RAAS) inhibitors  
- Angiotensin receptor neprilysin inhibitor (ARNI)  
- LCZ696 (LCZ)  
- Sacubitril‑valsartan (LCZ‑DPPV)  
- Isosorbide mononitrate  
- Cardiac amyloidosis  
- Transthyretin (TTR) amyloidosis  
- Wild‑type/transthyretin‑derived amyloidosis  
- Light‑chain (AL) amyloidosis  
- Transthyretin‑related amyloidosis (ATTR)  
- Cardiac imaging with planar technetium‑99m pyrophosphate (Tc‑99m‑PYP)  
- Quantitative kappa and lambda free‑light‑chain assays  
- Genetic testing for TTR mutation  
- Tafamidis therapy  
- Inotersen therapy  
- Patisiran therapy (RNA interference)  
- Diflunisal (repurposed)  
- Doxycycline plus ursodeoxycholic acid (TAU)  
- Green tea extract (observational therapy)  
- Intracardiac thrombosis / embolism  
- Anticoagulation therapy (in cardiac amyloidosis)  
- Implantable cardioverter‑defibrillator (ICD) outcomes  
- CHADS‑VASc score in TTR amyloidosis  
- Left atrial appendage thrombus  
- Advanced heart failure (stage D)  
- INTERMACS profiles of advanced HF  
- Specialist clinics for heart failure  
- Medication adherence / non‑adherence in HF  
- AHA/ACC/HFSA heart‑failure guideline statements  
- ACC/AHA/HFSA focused updates (2017, 2013, 2010)  
- Advanced heart‑failure position statements (European Society of Cardiology, American Heart Association)  
- Heart‑failure management in adults (ACC/AHA 2005 updated)  

These terms capture the core clinical conditions, diagnostic modalities, pharmacologic agents, and guideline frameworks discussed in the provided text.

Page 117 Extracted Terms:
- Heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular assist device (LVAD)  
- Heart transplantation  
- Mechanical circulatory support  
- Inotropic therapy  
- Dobutamine  
- Milrinone  
- Pulmonary hypertension  
- Congestion  
- Elevated jugular venous pressure (JVP)  
- Third heart sound (S3)  
- Hyponatremia  
- Sodium restriction  
- Fluid restriction  
- Cachexia  
- Obesity  
- Prognostic risk scores (e.g., Seattle Heart Failure Model, REMATCH, etc.)  
- Acute decompensated heart failure  
- Advanced heart failure (Stage D)  
- Diuretic therapy  
- Angiotensin‑converting‑enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARBs)  
- β‑adrenoceptor antagonists  
- Implantable cardioverter‑defibrillator (ICD)  
- Defibrillator shocks  
- Inotropic infusion  
- Repeated hospitalizations  
- Nutritional management (diet, sodium, fluid)

Page 118 Extracted Terms:
Heart failure  
Severe heart failure  
Acute heart failure  
Chronic heart failure  
Advanced heart failure  
Inotropic therapy  
Dobutamine infusion  
Milrinone infusion  
Levosimendan therapy  
Beta‑blocker therapy  
Calcium upregulation therapy  
Gene therapy (cardiac)  
Vasodilator therapy  
Mechanical circulatory support (MCS)  
Continuous‑flow device  
Magnetically levitated left ventricular assist device (LVAD)  
Heart‑Mate 3  
Heart‑Ware ventricular assist system (HVAD)  
Intrapericardial LVAD  
Cardiogenic shock  
Intra‑aortic balloon pump  
Bridge to transplant  
Bridge to recovery  
Bridge to cure  
Destination therapy  
Pulmonary hypertension (Group 2)  
Pulmonary vascular resistance  
Right ventricular failure  
Pump thrombus  
Antithrombotic therapy  
Neurologic events  
Quality of life  
Functional status  
Cost‑effectiveness analysis  
Frailty assessment  
InterMACS profiling  
INTERMACS profiles  
Heart transplant waiting list  
Survival outcomes  
Long‑term outcomes  
Clinical guidelines (heart failure)

Page 119 Extracted Terms:
- Heart failure  
- Advanced heart failure  
- End‑stage heart failure  
- Left ventricular assist device (LVAD)  
- Ventricular assist device (VAD)  
- Continuous‑flow LVAD  
- Mechanical circulatory support  
- Cardiac transplantation  
- Heart transplant  
- Donor‑recipient size match  
- Donor heart allocation  
- UNOS (United Network for Organ Sharing)  
- INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)  
- Right heart failure  
- Pulmonary hypertension  
- Congestive heart failure  
- Cardio‑pulmonary exercise testing  
- Peak VO₂ (peak oxygen uptake)  
- VE/VCO₂ slope  
- B‑type natriuretic peptide (BNP)  
- Cardiac output  
- Hemodynamics  
- Cardiogenic shock  
- Hypertrophic cardiomyopathy  
- Transthyretin amyloid cardiomyopathy  
- Cardiac amyloidosis  
- Muscular dystrophy (cardiac involvement)  
- Cardiac sarcoidosis  
- Congenital heart disease (advanced therapies)  
- Cardiac rehabilitation  
- Exercise capacity  
- Ventilatory efficiency  
- Invasive hemodynamics  
- Pre‑operative risk factors  
- Post‑operative risk factors  
- Neuro‑psychological complications  
- Device bridging to transplant  
- LVAD recovery  
- Device indications  
- Heart failure outcomes  
- Quality of life  
- Survival after transplantation  
- Transplant center volume  
- Recipient mortality  
- Clinical guidelines  
- AHA/ACC/HFSA guidelines  
- ESCAPE trial (clinical assessment of hemodynamics)  
- EVEREST trial (congestion in heart failure)  
- PROTECT trial (renal function in acute HF)  
- Cost‑effectiveness  
- Beta‑adrenergic blocker therapy  
- Heart transplant allocation policy changes  
- Left ventricular assist device trends and outcomes  
- Ventricular assist device therapy versus intensive medical therapy  
- Acute decompensated heart failure hospitalizations  
- Predictors of post‑discharge outcomes in acute heart failure  
- Ventricular assist device as a bridge to transplant  
- Donor heart allocation system (2018 revision)  
- Clinical phenotype classification in heart failure  
- Peak exercise oxygen consumption  
- Hemodynamic assessment during heart failure management  
- Cardiac function metrics (EF, stroke volume, etc.)  
- Inpatient monitoring of heart failure  
- Cardiac transplantation in patients with amyloidosis  
- Transplant outcomes in hypertrophic cardiomyopathy  
- Cardiac transplant in muscular dystrophy patients  
- Transplant outcomes in cardiac sarcoidosis  
- Transplant outcomes in congenital heart disease  
- Long‑term outcomes after heart transplantation.

Page 120 Extracted Terms:
- Heart failure  
- Acute heart failure  
- Acute decompensated heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Fulminant myocarditis  
- Ventricular arrhythmias  
- β‑blocker (beta‑blocker) therapy  
- Angiotensin‑converting enzyme inhibitor (ACE‑I)  
- Angiotensin receptor blocker (ARB)  
- Aldosterone antagonist (mineralocorticoid receptor blocker)  
- Diuretic therapy  
- Loop diuretic  
- Ultrafiltration  
- Guideline‑directed medical therapy (GDMT)  
- Systolic blood pressure  
- Blood pressure management  
- Renal function (worsening renal function, tubule injury)  
- Cardiorenal syndrome  
- Congestion (in‑hospital and residual)  
- Ejection fraction assessment  
- Diuretic strategies (decongestion strategy)  
- Convergent classification of heart failure (ejection fraction categories, clinical presentation)

Page 121 Extracted Terms:
**Key heart‑disease terms identified in the excerpt**

- Heart failure
- Acute decompensated heart failure
- Chronic heart failure
- Ventricular dysfunction (left‑ventricular systolic dysfunction)
- Cardiogenic shock
- Acute myocardial infarction
- Venous thromboembolism (VTE) prophylaxis
- Renal function / creatinine
- Congestion / residual congestion
- Inotropic agents (milrinone, dobutamine, dopamine, epinephrine, norepinephrine)
- Vasodilators (nesiritide, nitroglycerin, nitroprusside, clevidipine)
- Diuretics (furosemide, ultrafiltration, aquapheresis)
- Mechanical circulatory support (Impella, short‑term mechanical support)
- Anticoagulants / thromboprophylaxis (enoxaparin, unfractionated heparin, rivaroxaban, cerotaparin)
- Thrombotic biomarkers
- Left‑ventricle characteristics
- Hemodynamic response / hemodynamics
- Lactate metabolism
- Mortality / survival outcomes
- Rehospitalization
- Prognostic significance
- Aggressive decongestion
- Dose‑response to low‑dose dopamine / nesiritide
- Vascular tolerance (nitrate tolerance)
- Hemodynamic effects of continuous infusion
- Mechanical support utilization trends
- Inotrope strategies
- Pharmacologic therapy in heart failure guidelines
- AHA/ACC/HFSA Heart Failure Guideline
- AHA/ACC/HFSA 2022 Heart Failure Guideline
- Acute heart failure with preserved vs. reduced ejection fraction

These terms capture the clinical concepts, therapeutic agents, interventions, and outcome measures related to heart disease that appear throughout the provided guidelines and study references.

Page 122 Extracted Terms:
- Cardiogenic shock  
- Mechanical circulatory support  
- Intra‑aortic balloon pump (IABP)  
- Impella device  
- Ventricular assist device (VAD)  
- TandemHeart  
- Veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Pulmonary artery catheter  
- Acute myocardial infarction  
- Heart failure (HF)  
- Acute heart failure  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Cardiac shock care centers  
- Shock team approach  
- Cardiogenic shock protocols / shock protocols  
- Transition / transitional care interventions  
- Discharge education  
- Hospital‑based discharge medication program  
- Heart failure disease management  
- Performance improvement initiative  
- OPTIMIZE‑HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)  
- Survival after veno‑arterial ECMO (SAVE) score  
- National cardiogenic shock initiative  
- Hemodynamic monitoring & profiling  
- Acute management of cardiogenic shock


Page 123 Extracted Terms:
- Heart failure  
- Acute myocardial infarction  
- Pneumonia  
- Transitions of care  
- Evidence‑based pharmacotherapy  
- 30‑day readmission  
- Continuous positive airway pressure  
- Adaptive servo‑ventilation  
- Central sleep apnea  
- Positive airway pressure therapy  
- Iron deficiency  
- Intravenous iron therapy (ferric carboxymaltose)  
- Anemia  
- Erythropoiesis‑stimulating therapy (darbepoetin alfa, erythropoietin)  
- SGLT2 inhibitors (dapagliflozin, empagliflozin)  
- Blood‑pressure management  
- Intensive blood‑pressure control  
- Depression in heart failure  
- Major depression therapy (escitalopram, sertraline)  
- Kidney disease / chronic kidney disease  
- Polypharmacy  
- Multimorbidity  
- Clinical practice guideline implementation  
- Heart‑failure readmission intervention (e.g., THRIVE, THRIVE)  
- Variable early follow‑up  
- ESCAPE risk model / discharge score  
- Hospital performance metrics (30‑day all‑cause readmission)  
- Management of comorbidities  
- Exercise capacity  
- Mortality risk  
- Pharmacological interventions (e.g., iron, ACE inhibitors, beta‑blockers, ARNI)  
- Clinical outcomes  
- Meta‑analysis  
- Randomized clinical trial  
- Systematic review  
- Evidence‑based interventions  
- Quality improvement initiatives



Page 124 Extracted Terms:
Heart failure  
Reduced ejection fraction heart failure  
Preserved ejection fraction heart failure  
Heart failure with mildly reduced ejection fraction (HFmrEF)  
Systolic heart failure  
Left ventricular systolic dysfunction  
Dilated cardiomyopathy (implied in HF context)  
Atrial fibrillation (AF)  
Paroxysmal atrial fibrillation  
Persistent atrial fibrillation  
Permanent atrial fibrillation  
Valvular atrial fibrillation (non‑valvular)  
Atrial fibrillation‑associated thromboembolism  
Thromboembolic risk  
CHA₂DS₂-VASc score  
Stroke prevention in AF  
Anticoagulation therapy  
Warfarin  
Dabigatran  
Rivaroxaban  
Apixaban  
Edoxaban  
Novel oral anticoagulants (NOACs)  
Anticoagulant therapy in heart failure  
Rate control in AF  
Rhythm control in AF  
Catheter ablation for AF  
Atrioventricular junction ablation  
Cardiac resynchronization therapy (CRT)  
Biventricular pacing  
Right‑ventricular pacing  
Left‑ventricular pacing  
Cardiac pacing after AV nodal ablation  
Cardiac tamponade (implied within HF context)  
Electrical cardioversion  

Blood pressure management  
Hypertension  
Intensive blood pressure lowering  
ACC/AHA guideline for hypertension  

Sleep‑disordered breathing  
Central sleep apnea  
Sleep‑apnea therapy  
Continuous positive airway pressure (CPAP)  
Positive airway pressure therapy  

Diabetes mellitus (type 2)  
Glycemic treatment strategies  
Sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors  
Empagliflozin  
Canagliflozin  
Ipragliflozin  
Sotagliflozin  
Dapagliflozin  

Cardiovascular endpoints  
Mortality  
Hospitalization for heart failure  
Heart failure events  
Morbidity  

Clinical trials related to heart failure  
DELIVER (dapagliflozin trial)  
EMPEROR‑Preserved (empagliflozin trial)  
SAD, etc. (implied in references)  

Guideline documents  
AHA/ACC/HFSA Heart Failure Guideline  
ACC/AHA/NMA/PCNA hypertension guideline  
ESC guideline for atrial fibrillation  
AHA/ACC/HRS guideline for atrial fibrillation  

Key biomarkers  
Brain natriuretic peptide (BNP)  
Natriuretic peptide levels  

Metabolic therapies  
Insulin resistance  
Metformin (implied via glycemic control)

Cardiac imaging (implied)  
Ejection fraction measurement  
Left ventricular dysfunction assessment  

Page 125 Extracted Terms:
Heart failure  
Congestive heart failure  
Heart failure hospitalization  
Heart failure incidence  
Heart failure survival  
Heart failure mortality  
Heart failure management  
Heart failure guidelines  
Heart failure clinics  
Heart failure patients  
Heart failure in older adults  
Heart failure in women  
Heart failure in black patients  
Heart failure in Hispanic/Latino adults  
Heart failure in American Indian/Alaska Native adults  
Heart failure in Asian American/Pacific Islander adults  
Heart failure risk  
Heart failure disparities  
Heart failure referrals  
Heart failure outcomes  
Implantable cardioverter‑defibrillator therapy  
Cardioverter‑defibrillator therapy  
Cardiac surgery  
Cardiac rhythm  
Cardiology  
Cardiologists  
Cardiovascular disease  
Cardiovascular outcomes  
Cardiovascular morbidity  
Cardiovascular mortality  
Cardiovascular health  
Hypertension  
High blood pressure  
Diabetes  
Diabetes in heart failure  
Comorbidities  
Socioeconomic status  
Socioeconomic deprivation  
Neighborhood deprivation  
Racial disparities  
Ethnic disparities  
Sex differences  
Gender disparities  
Structural racism  
Social determinants of health  
Elderly  
Older adults  
Skilled nursing facility care  
Chagas’ disease  
Trypanosoma cruzi infection  
Stroke  
Ischemic stroke  
Stroke in heart failure  
High blood pressure prevention  
Cardiovascular epidemiology  
Cardiovascular epidemiology in diverse populations

Page 126 Extracted Terms:
- Heart disease  
- Cardiovascular disease  
- Heart failure  
- Congestive heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular assist device (LVAD)  
- Heart transplantation / heart transplant  
- Atrial fibrillation  
- Cardiomyopathy  
- Cardiotoxicity  
- Anthracycline‑induced cardiomyopathy  
- Trastuzumab‑related cardiotoxicity  
- Trastuzumab‑associated heart failure  
- Cardiac events  
- Cardiovascular risk factors  
- Ejection fraction  
- Hypertension  
- Stroke  
- Cardiovascular clinical trials  
- Advanced heart failure therapies  
- Cardio‑oncology  
- Chemotherapy‑related cardiac monitoring  
- Cardiac monitoring  
- Cardiovascular health disparities  
- Cardiovascular epidemiology  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cardiac outcomes  
- Cardiac monitoring via echocardiography  
- Cardiac tolerance/long‑term cardiac tolerance  
- Cardiovascular disease in specific populations (Hispanic, African American, Asian, South Asian, American Indian)  
- Cardiovascular disease risk statistics  
- Cardio‑oncological chemotherapy agents (anthracyclines, trastuzumab)  
- Cardiac function assessment  
- Cardiac imaging (echocardiography)  
- Cardiac therapy adherence.

Page 127 Extracted Terms:
- Cardiovascular disease  
- Heart failure (HF)  
- Congestive heart failure  
- Left ventricular dysfunction (LVD)  
- Left ventricular ejection fraction (LVEF)  
- Cardiomyopathy (anthracycline‑induced, trastuzumab‑induced, doxorubicin‑related)  
- Trastuzumab cardiotoxicity  
- Anthracycline‑induced cardiotoxicity  
- Chemotherapy‑related cardiotoxicity  
- Immune‑checkpoint‑inhibitor–induced myocarditis  
- Cardiac dysfunction (clinical & subclinical)  
- Cardio‑oncology / cardio‑oncological prevention  
- Cardiac monitoring (baseline, longitudinal)  
- Biochemical cardiac biomarkers  
  - Troponin I  
  - Troponin T  
  - N‑terminal pro‑B type natriuretic peptide (NT‑proBNP)  
- Myocardial performance index (MPI)  
- Neurohormonal therapies for cardioprotection  
  - Beta‑blockers (e.g., carvedilol, metoprolol)  
  - Angiotensin‑converting‑enzyme inhibitors (ACEi, e.g., enalapril, lisinopril)  
  - Angiotensin II receptor blockers (ARBs, e.g., candesartan)  
  - Mineralocorticoid receptor antagonists (spironolactone)  
- Preventive strategies (e.g., ACEi/ARB, β‑blockers, carvedilol, spironolactone)  
- Cardiotoxicity risk stratification  
- Cardiovascular hospitalizations  
- Cardiovascular mortality  
- Cardiac safety monitoring in cancer therapy  
- Clinical guidelines for heart failure (AHA/ACC/HFSA)  

These terms capture the core heart‑related concepts discussed across the cited clinical statements and studies.

Page 128 Extracted Terms:
- Cardiotoxicity  
- Cardiac dysfunction  
- Myocarditis  
- Pericarditis  
- Heart failure  
- Cardiovascular complications  
- Cardiovascular toxicity  
- Cardiac adverse effects  
- Cardiac safety  
- Vascular toxicity  
- Coronary artery stenosis  
- Arrhythmia  
- Cardiovascular events  
- Ventricular dysfunction  
- Left ventricular dysfunction  
- Cardiac injury  
- Myocardial damage  
- Radiotherapy‑associated heart disease  
- Anthracycline‑related cardiotoxicity  
- Tyrosine kinase inhibitor‑associated cardiovascular toxicity  
- BRAF‑inhibitor‑related cardiotoxicity  
- Immune checkpoint‑inhibitor‑associated myocarditis  
- Cardiac mortality  
- Serious cardiac complications during transplantation  
- Short‑term cardiac toxicity (post‑transplant)  
- Long‑term heart failure after radiotherapy


Page 129 Extracted Terms:
- Heart failure  
- Peripartum cardiomyopathy  
- Dilated cardiomyopathy  
- Pregnancy‑associated heart disease  
- Postpartum cardiomyopathy  
- Cardiovascular disease during pregnancy  
- Pre‑pregnancy counseling for heart disease  
- Maternal outcomes  
- Fetal outcomes  
- Maternal‑fetal outcomes  
- Left ventricular ejection fraction  
- Right ventricular dysfunction  
- Cardiogenic shock  
- Bromocriptine therapy  
- Prolactin cleavage (cathepsin‑D cleaved prolactin)  
- Genetic predisposition to cardiomyopathy  
- Titin (TTN) gene mutations  
- PTHLH gene locus (chromosome 12p11.22)  
- Hypertensive diseases of pregnancy  
- Preeclampsia  
- Left ventricular recovery  
- Clinical phenotyping of cardiomyopathy  
- Risk prediction models for peripartum cardiomyopathy  
- Registry data on peripartum cardiomyopathy  
- ESC guidelines for cardiovascular disease in pregnancy  
- AHA/ACC/HFSA heart‑failure guideline  
- JACC state‑of‑the‑art review on cardiovascular drugs in pregnancy  
- Scientific statement on dilated cardiomyopathy diagnostics and treatment  
- Randomized controlled trials of bromocriptine in peripartum cardiomyopathy  
- Meta‑synthesis of women’s experiences with cardiac disease in pregnancy  
- Observational cohort studies on peripartum cardiomyopathy outcomes  
- Clinical characteristics and outcomes in pregnancy‑associated heart failure.

Page 130 Extracted Terms:
peripartum cardiomyopathy  
cardiovascular outcomes  
pregnancy in women with cardiomyopathy  
postpartum cardiovascular outcomes  
inherited cardiomyopathies  
pregnancy with heart failure  
high‑risk cardiac disease in pregnancy  
cardiac risk assessment  
pregnancy outcomes in women with heart disease  
congenital heart disease  
left ventricular assist device  
implantable cardioverter‑defibrillators  
palliative care  
hospice care  
advance care planning  
left ventricular recovery  
cardiomyopathy and preeclampsia  
B‑type natriuretic peptide  
N‑terminal pro‑B‑type natriuretic peptide  
Bromocriptine  
breastfeeding in heart failure  
heart failure  
acute myocardial infarction  
cardiovascular complications  
cardiac disease in pregnancy  
cardiovascular disease

Page 131 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Heart failure  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Congestive heart failure  
- Aortic valve replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Mitral valve repair  
- Left ventricular dysfunction  
- Coronary artery bypass grafting (CABG)  
- Myocardial infarction (AMI)  
- Pulmonary artery hemodynamic monitoring  
- Cardiac resynchronization therapy (CRT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Atrial fibrillation  
- Pulmonary‑vein isolation (for AF)  
- Heart failure registry (e.g., CHAMP‑HF, EVEREST, I‑PRESERVE, SOLVD)  
- Kansas City Cardiomyopathy Questionnaire (KCCQ)  
- Minnesota Living with Heart Failure Questionnaire (MLHFQ)  
- New York Heart Association (NYHA) functional classification  
- Health‑related quality of life (HRQoL)  
- Patient‑reported outcomes (PROs)  
- Hospitalization risk  
- Mortality risk  
- Prognostic biomarkers  
- Symptom burden  
- Palliative care for heart disease  
- Advance care planning  
- End‑of‑life care  
- Cardiovascular mortality  

These terms capture the primary conditions, interventions, measurement tools, outcomes, and care concepts relevant to heart disease that appear throughout the referenced guideline and study citations.

Page 132 Extracted Terms:
- Heart Failure  
- Heart Failure Guideline (AHA/ACC/HFSA)  
- Advanced Heart Failure  
- Heart Transplant  
- Mechanical Circulatory Support (MCS)  
- Cardiology  
- Cardiovascular Medicine  
- Heart Failure Society of America (HFSA)  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)

Page 133 Extracted Terms:
- Heart Failure  
- HF  
- Heart Disease  
- Cardiovascular  
- Cardiology  
- Cardiac  
- Cardiac Electrophysiology  
- Advanced Heart Failure  
- Heart Failure Guideline  
- Heart Failure Society of America (HFSA)  
- Transplantation  
- HFSA Heart Failure Guideline  
- Cardiovascular Medicine  
- Heart Failure Management  
- Cardiology Department  
- Cardiac Care

Page 134 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

1. Heart Failure  
2. Heart Disease  
3. Cardiovascular Disease  
4. Cardiovascular Medicine  
5. Cardiology  
6. Cardiomyopathy  
7. 2022 AHA/ACC/HFSA Heart Failure Guideline  
8. American Heart Association (AHA)  
9. American College of Cardiology (ACC)  
10. Heart Failure Society of America (HFSA)  
11. Clinical Statements  
12. Guideline Advisor  
13. Committee Member  
14. Clinical Trial Enroller  
15. Device (as used in cardiac therapy)  
16. Drug (as used in cardiac therapy)  
17. Heart Failure Management  
18. Cardiac Diagnostics  
19. Cardiac Interventions  
20. AHA/ACC/HFSA Guideline  

*(The list captures the central cardiovascular topics, organizations, and clinical concepts referenced in the document.)*

Page 135 Extracted Terms:
- Heart failure  
- Heart failure management  
- Heart failure guideline  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- Cardiovascular disease  
- Cardiology  
- Pulmonary hypertension  
- Circulation (journal)  
- Clinical practice guidelines  
- Clinical statements  
- Management of heart failure  
- Heart disease  

These terms capture the primary concepts related to heart disease discussed in the provided guideline excerpt.

Page 136 Extracted Terms:
- Heart Failure  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- AHA/ACC/HFSA Heart Failure Guideline  
- Circulation (cardiology journal)  
- Heartflow (cardiovascular imaging/diagnostics platform)  
- Medtronic (cardiovascular device manufacturer)  
- NuPulse CV (cardiovascular technology)  
- CVRx (cardiovascular research/therapy company)  
- Cardiovascular  
- Cardiovascular & Risk Reduction Center  
- JAMA (medical journal covering cardiovascular topics)  
- NIH (National Institutes of Health, many cardiovascular research programs)

Page 137 Extracted Terms:
**Key Terms Related to Heart Disease**

- Heart failure  
- HFSA (Heart Failure Society of America)  
- AHA/ACC/HFSA Heart Failure Guideline  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- Cardiology / Cardiovascular health  
- Pulmonary hypertension  
- Pulmonary Hypertension Association  
- Cardiology Fellowship Program  
- US Food and Drug Administration (FDA)  
- Centers for Medicare & Medicaid Services (CMS)  
- Medical device manufacturers related to cardiac care:  
  - Abbott  
  - Medtronic  
  - Boston Scientific  
  - Cardiora  
  - CVRx  
- Pharmaceutical companies with cardiac indications:  
  - AbbVie (Bristol Myers Squibb)  
  - Amgen  
  - AstraZeneca Pharmaceuticals*  
  - Bayer  
  - Boehringer Ingelheim  
  - GlaxoSmithKline  
  - Eli Lilly  
  - Merck  
  - Pfizer  
  - Sanofi  
  - Novartis*  
  - Novo Nordisk  
  - United Therapeutics (Pulmonary Hypertension Association)  
  - Janssen Pharmaceuticals  
  - Myokardia  
  - Ionis  
  - Prothena  
  - Regeneron  
  - Shifamed  
  - Tenax  
  - Ironwood  
  - Cytokinetics  
  - Vascular/heart‑related biotech: Cytokinetics, CVRx, Cyclerion, etc.  
- Regulatory/industry advisory organizations:  
  - National Institutes of Health (NIH)  
  - Clinical Practice Guidelines (Joint Committee)  
- Specialty hospitals and academic centers in cardiology:  
  - St. Vincent Hospital  
  - Northwestern University  
  - Yale University  
  - University of Pennsylvania  
  - University of North Carolina  
  - University of Arizona  
  - Mount Sinai  

These terms encompass cardiovascular conditions, professional societies, regulatory bodies, medical device and pharmaceutical companies, and academic institutions that are directly relevant to the field of heart disease.

Page 138 Extracted Terms:
- Heart failure (HF)  
- Structural heart disease  
- Increased filling pressures  
- Left atrial volume index (LAVI)  
- Left ventricular mass index (LVMI)  
- Relative wall thickness (RWT)  
- Left ventricular wall thickness  
- Left ventricular ejection fraction (LVEF)  
- Global longitudinal strain (GLS)  
- E/e′ ratio  
- Septal e′ velocity  
- Lateral e′ velocity  
- Tricuspid regurgitation (TR) velocity  
- Pulmonary artery systolic pressure (PASP)  
- Brain natriuretic peptide (BNP)  
- N‑terminal proBNP (NT‑proBNP)  
- Atrial fibrillation (AF)  
- Chronic kidney disease (CKD)  
- Diagnostic biomarkers for heart failure  
- Echocardiographic assessment (echo)  
- Ventricular systolic function  
- Ventricular diastolic function  
- Diastolic dysfunction  
- Thrombolysis in Myocardial Infarction (TIMI)  
- Pulmonary Embolism Response Team (PERT)  

These terms capture the key concepts and measurements relevant to heart disease discussed in the provided guideline excerpt.

